Development and Evaluation Controlled Release Diclofenac Sodium Matrix Tablets by Ahmed, Abdalla
DEVELOPMENT AND EVALUATION OF 
CONTROLLED RELEASE DICLOFENAC SODIUM 
MATRIX TABLETS 
 
By 
 
Abdalla Ahmed Abdalla Gargar 
(M. Pharm.1986) 
 
Submitted for the Doctor of Philosophy in Pharmaceutical Technology 
Department of Pharmaceutics 
Faculty of Pharmacy 
University of Khartoum 
 
 
 
 
 
 
July 2006 
 Dedication 
 
Dedicated To my parents, my small family 
(My Wife, my children) 
and to Dr. Hussein Mustafa Ali 
who encouraged me to 
complete my study 
 i
Acknowledgement 
All my praises and thanks to Almighty AllA  the  lord of all 
Universe for his help to complete all this work. My thanks and gratitude 
to my supervisory team Dr. Abdulkarim Mohmed Abdulkarim and Dr. 
Elamin Ibrahim Elnima for their supervision, guidance reviews and 
fruitful discussion ,which enabled me to finish this work at the stated 
time. 
My thanks to the National fund for promotion of medical services 
for partial funding of the study. 
We thank Mr. Von Valtier Senior for his help to obtain some 
materials. 
Also I wish to acknowledge Dr. Abukakr Alkhorashi from Rabat 
University for his advice. We also thank Professor Mohamed Zain who 
helped in interpretation of some analytical results. 
My thanks also to Mr. Suleiman Ibrahim and Miss Randa Hassan   
Mohamed Osman for their help in taking the samples and instrumental 
analysis. 
The last and not the least my thanks to Amal Alsamani Altaib  who 
printed this work and Mr Altahir for the final copy. 
 ii
Abstract 
In vitro release profiles were studied for the matrix controlled 
release Diclofenac sodium tablets (MT20, MT33, MT34)  in comparison 
with Voltaren retard (V.R) a well known marketed Diclofenac sodium 
controlled release tablets from Novartis® (Switzerland). Percentage 
release of Diclofenac sodium was studied in gradient pHS (1.2, 2.1, 4.2, 
5.5, 6.5, 6.7, & 7.2) in accordance with gastric pHS, which are varying 
from pH one to eight. The study included the release profiles and 
evaluated the kinetics of diffusion and diffusion exponents. 
Analysis of new controlled release oral drug delivery systems using, C8 
(Eurosphere-100 (5 µm) 4.6 mm ID x 250 mm) and C18 (Eurosphere-100 
(5 µm) 4 mm ID x 100 mm) columns was carried out. The mobile phase 
was phosphate buffer/methanol. Spectrophotometric detection was at 272 
nm. Percentages of content for the different matrices were evaluated.  
Based on t-test no significant difference was found between 
content measurements using C8 and C18 columns at p′-value of 0.05. 
(Observed t-value was 0.062 compared to the theoretical value of 2.15. 
Content analysis showed good precision and accuracy with C8 rather than 
C18. 
In vivo performance and bio-equivalence of controlled release 
matrix tablets (MT33) containing gum Arabic and Guar gum was 
compared to a standard control drug Voltaren retard in healthy male  
volunteers.  
 The study design was randomized cross-over study. Blood samples 
were collected at pre-determined periods, up to 12 hours and one sample 
was taken after 24 hours.  
High performance liquid chromatographic (HPLC) analysis was 
done for both sample and control. Parameters such as Cmax, Tmax, AUC0-24, 
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Kel and MRT0-24. AUMC0-t, AUMC0-∞ were obtained. The bio-
equivalence of both formulations was evaluated which showed no 
difference in prolonged action  in vivo performance between controlled 
matrix tablets (MT33 ) containing gum Arabic  and guar gum   compared 
to a standard control drug ; Voltaren retard in healthy volunteers.  
Accelerated stability study for six months was performed for 
controlled release matrix tablets (MT20, MT33, MT34, MT33p, MT34p) 
containing natural gums (gum Arabic, guar gum), semi-synthetic gum 
(Xanthan gum), Eudragit L100 (methacrylic acid and methyl 
methacrylate), and Hydroxypropylmethylcellulose. 
  Microbiological tests for matrices were evaluated by comparing 
preserved and non preserved tablets. Content was found to be 90-105% in 
all the five matrix formulae. Applying out of trend stability rules (OOT), 
the best formula was MT33 which contain guar gum 15% and gum 
Arabic 15%. No changes in physical appearance and organoleptic 
properties were observed. No microbiological growth (bacteria or fungi) 
was observed in both preserved and non-preserved controlled release 
formulae. 
vi 
  ﺑﺴﻢ ﺍﷲ ﺍﻟﺮﺣﻤﻦ ﺍﻟﺮﺣﻴﻢ
  اﻟﻌﺮﺑﻲ ﻟﻠﺪراﺳﺔﺨﺺ اﻟﻤﻠ
ﺠﺩﻴﺩﺓ ﺒﺄﺴﺘﻌﻤﺎل ﺍﻟﺼﻤﻎ ﺍﻟﻌﺭﺒﻰ ﻭﺼﻤﻎ  ﻘﻨﻴﺔ ﺘﻹﻴﺠﺎﺩﺘﻬﺩﻑ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ 
 ﻤﻠﺠﻡ 001 ﻤﺴﺘﺤﻀﺭ ﺍﻟﺩﺍﻴﻜﻠﻭﻓﻴﻨﺎﻙ ﺼﻭﺩﻴﻭﻡ ﻹﻨﺘﺎﺝ ﻨﺴﻴﺞ ﻀﺎﻡ ﻤﻨﺎﺴﺏ ﻹﻴﺠﺎﺩ ﺍﻟﻘﻭﺍﺭ
ﻭﻗﺩ ﺘﻡ ﺘﺤﻀﻴﺭ ﻋﻴﻨﺎﺕ ﻤﻥ . ﻭﻫﻭ ﺍﺤﺩ ﻤﺴﻜﻨﺎﺕ ﺍﻷﻟﻡ ﺍﻟﺸﺎﺌﻌﺔ ﺫﻭ ﺍﻟﻤﻔﻌﻭل ﺍﻟﻁﻭﻴل 
ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﺒﺎﺴﺘﻌﻤﺎل ﺍﻟﺼﻤﻎ ﺍﻟﻌﺭﺒﻲ ﻭﺼﻤﻎ ﺍﻟﻘﻭﺍﺭ ﻭﺼﻤﻎ ﺍﻻﻜﺯﻨﺘﺎﻥ ﻫﺫﻩ 
   .001 ﻤﺜﻴل ﺴﻴﻠﻠﻭﺯ ﻭﺍﻻﻴﺩﺭﺍﺠﻴﺕ ل لﺒﺭ ﻭﺒﻴﻭﻫﻴﺩﺭﻭﻜﺴﻲ 
 ﺍﻟﺩﺍﻴﻜﻠﻭﻓﻴﻨﺎﻙ ﺘﺤﺭﺭ ﺘﻤﺕ ﺩﺭﺍﺴﺔ ﻭﺒﺎﺴﺘﻌﻤﺎل ﻁﺭﻕ ﺍﻟﺘﺤﻠﻴل ﺍﻟﻤﺨﺘﻠﻔﻪ   
ﺒﻪ ﺸ ﻭﺴﺎﺌﻁ ﺫﺍﺕ ﺩﺭﺠﺎﺕ ﺤﻤﻀﻴﻪ ﻭﻗﺎﻋﺩﻴﺔ ﻭﻓﻲﺼﻭﺩﻴﻭﻡ ﻓﻲ ﻫﺫﻩ ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ 
ﻤﻘﺎﺭﻨﺔ ﻫﺫﻩ ﻭ  . ﻗﻨﺎﺓ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲﻓﻲ ﺘﻭﺠﺩ ﻟﺘﻲﺍﻤﺘﻌﺎﺩﻟﺔ ﻤﻤﺎﺜﻠﺔ ﻟﺘﻠﻙ 
( ﺴﻭﻴﺴﺭﻯ ﺍﻟﻤﻨﺸﺄ)ﻫﻭ ﻓﻭﻟﺘﺎﺭﻴﻥ ﺭﻴﺘﺎﺭﺩ ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﻤﻊ ﻤﺴﺘﺤﻀﺭ ﻗﻴﺎﺴﻲ 
ﻜﻤﺎ . ﺒﺎﺴﺘﻌﻤﺎل ﺠﻬﺎﺯ ﺍﻟﺫﻭﺒﺎﻥ ﻭﻓﻕ ﻁﺭﻕ ﺩﺴﺘﻭﺭ ﺍﻷﺩﻭﻴﺔ ﺍﻟﺒﺭﻴﻁﺎﻨﻰ ﻭﺍﻷﻤﺭﻴﻜﻰ.
  .ﺩﺭﺍﺴﺔ ﺤﺭﻜﻴﺔ ﺍﻻﻨﺘﺸﺎﺭ ﻟﻬﺫﻩ ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﺍﻟ ﺸﻤﻠﺕ 
  ﻜﻭﻤﺎﺘﻭﻗﺭﺍﻓﻴﺎﺠﻬﺎﺯﺘﺤﻀﺭﺍﺕ ﺒﺎﺴﺘﻌﻤﺎل ﺘﺤﻠﻴل ﻫﺫﻩ ﺍﻟﻤﺴﺸﻤﻠﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ   
 ﻭﻤﺤﻠﻭل ﻓﺼل 8 ﻭﺱ 81 ﻓﺼل ﺱ ﻋﻤﻭﺩﻱ ﺒﺎﺴﺘﻌﻤﺎل ﺍﻟﻀﻐﻁ ﺍﻟﻌﺎﻟﻲ ﺍﻟﺴﺎﺌل ﺫﻭ
 (  ﺤﺠﻡ66)ﻤﻴﺜﺎﻨﻭل (  ﺤﺠﻡ43) 5.2  ﻤﺘﻌﺎﺩل  ﺍﻟﻔﻭﺴﻔﺎﺕ ﺒﺘﺭﻜﻴﺯ ﻫﻴﺩﺭﻭﺠﻴﻨﻲ  ﻤﺤﺩﺩ
  . ﺒﺎﺴﺘﻌﻤﺎل ﻁﺭﻕ ﺇﺤﺼﺎﺌﻴﺔ ﻤﺤﺩﺩﺓ ﻴﻘﺘﻴﻥ ﺍﻟﻁﺭﺎﺘﻴﻥﺘﻤﺕ ﻤﻘﺎﺭﻨﺔ ﻫﻭ
ﻟﻬﺫﻩ ﺍﻟﻤﺭﻜﺒﺎﺕ ﻓﻲ ﺩﺭﺠﺔ ﺤﺭﺍﺭﺓ ( ﺍﺸﻬﺭﺴﺘﺔ )ﻜﻤﺎ ﺘﻤﺕ ﺩﺭﺍﺴﺔ ﺜﺒﺎﺕ ﺴﺭﻴﻌﺔ 
 (  . ﺭﻁﻭﺒﺔ ﻨﺴﺒﻴﻪ%57 ﺩﺭﺠﻪ ﻤﺌﻭﻴﺔ ﻭ 04)ﻭﺭﻁﻭﺒﺔ ﻗﻴﺎﺴﻴﺔ 
 ﻭﺸﻤﻠﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻜل ﺍﻷﻗﺭﺍﺹ ﺍﻟﺘﻲ ﺘﺤﺘﻭﻯ ﻋﻠﻰ ﺼﻤﻭﻍ ﻭﻤﻭﺍﺩ ﺤﺎﻓﻅﺔ 
ﻭﺘﻡ ﺘﻘﻴﻴﻡ ﻨﻤﻭ ﺍﻟﺒﺎﻜﺘﺭﻴﺎ . ﻟﻤﻌﺭﻓﺔ ﻤﺩﻯ ﻭﺠﻭﺩ ﺘﻠﻭﺙ ﺃﻭ ﺒﻜﺘﺭﻴﺎ ﻓﻰ ﻫﺫﻩ ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ 
ﻭﺒﻌﺩ ﺴﺘﺔ ﺃﺸﻬﺭ ﻤﻥ ﺍﻟﺩﺭﺍﺴﺔ . ﻁ ﻤﻨﺎﺴﺒﺔﻭﺍﻟﻔﻁﺭﻴﺎﺕ ﻓﻲ ﻫﺫﻩ ﺍﻟﻌﻴﻨﺎﺕ ﺒﺎﺴﺘﻌﻤﺎل ﻭﺴﺎﺌ
ﺍﻟﻤﺴﺘﻤﺭﺓ ﻟﻡ ﻴﺘﻡ ﺍﻟﺤﺼﻭل ﻋﻠﻰ ﻤﻠﻭﺜﺎﺕ ﺍﻟﺒﺎﻜﺘﺭﻴﺎ ﻭﺍﻟﻔﻁﺭﻴﺎﺕ ﻭﺨﻠﻭ ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ 
ﻤﻤﺎ ﻴﻌﺯﺯ ﻓﻜﺭﺓ ﺃﺴﺘﻌﻤﺎل ﻫﺫﻩ ﺍﻟﺼﻤﻭﻍ ﻓﻰ ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ . ﻤﻥ ﺍﻟﺒﺎﻜﺘﺭﻴﺎ ﺍﻟﻤﻤﺭﻀﺔ
  .ﺍﻟﺼﻴﺩﻻﻨﻴﺔ ﺍﻟﺠﺎﻓﺔ
v 
ﻊ  ﻭﻤﻘﺎﺭﻨﺘﻪ ﻤ33 TMﻜﺫﻟﻙ ﺍﺠﺭﻴﺕ ﺩﺭﺍﺴﺔ ﺍﻟﺘﻜﺎﻓﺅ ﺍﻟﺤﻴﻭﻱ ﻟﻠﻤﺭﻜﺏ ﺍﻟﻨﻬﺎﺌﻲ 
ﺘﻡ ﺍﺨﺫ ( 21ﻋﺩﺩ )ﻤﺭﻜﺏ ﻗﻴﺎﺴﻲ ﻫﻭ ﻓﻭﻟﺘﺎﺭﻴﻥ ﺭﻴﺘﺎﺭﺩ ﻓﻲ ﻋﻴﻨﺎﺕ ﻤﻥ ﺍﻟﻤﺘﻁﻭﻋﻴﻥ 
ﻭﻓﺼل ﺍﻟﺒﻼﺯﻤﺎ ﻭﺘﺤﻠﻴل ﻨﺴﺒﺔ ﺘﺭﻜﻴﺯ .  ﺴﺎﻋﺔ 42ﻋﻴﻨﺎﺕ ﻤﻥ ﺍﻟﺩﻡ ﻜل ﺴﺎﻋﺔ ﻭﻟﻤﺩﺓ 
ﻭﺤﺴﺎﺏ ﺍﻟﻤﻘﺎﻴﻴﺱ ﺍﻟﺤﺭﻜﻴﺔ ﻟﻠﺩﻭﺍﺀ ﻭﻓﻕ  . ﺍﻟﺩﻭﺍﺀ ﻓﻰ ﺍﻟﺒﻼﺯﻤﺎ ﺨﻼل ﻓﺘﺭﺓ ﺍﻟﺩﺭﺍﺴﺔ 
 ﻤﻊ ﺍﻟﻤﺴﺘﺤﻀﺭ ﺍﻟﻘﻴﺎﺴﻲ 33 TMﻭﺒﻤﻘﺎﺭﻨﺔ ﺍﻟﻤﺴﺘﺤﻀﺭ . ﻁﺭﻕ ﺇﺤﺼﺎﺌﻴﺔ ﻤﺤﺩﺩﺓ 
ﻓﻭﻟﺘﺎﺭﻴﻥ ﺭﻴﺘﺎﺭﺩ ﻭﺠﺩ ﺒﺄﻨﻪ ﻟﻴﺱ ﻫﻨﺎﻟﻙ ﻓﺭﻕ ﺫﻭ ﻗﻴﻤﻪ ﺒﻴﻥ ﺍﻟﻤﺴﺘﺤﻀﺭﻴﻥ ﺒﺎﺴﺘﻌﻤﺎل 
  .ﻁﺭﻕ ﺍﻟﺘﺒﺎﻴﻥ ﺍﻹﺤﺼﺎﺌﻴﺔ ﻤﻤﺎ ﻴﺅﻜﺩ ﺠﻭﺩﺓ ﺍﻟﻤﻨﺘﺞ ﻭﻓﻌﺎﻟﻴﺘﻪ 
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Chapter I  
1.1 Introduction and literature review 
Controlled release formulation is to give a drug at predetermined 
rate, maintaining a constant drug level in the body for longer period, with 
concomitant minimizing of undesirable side effects (1). 
Solid matrix controlled release is usually prepared by incorporation 
of a drug into a bed, with physical or chemical properties to release a 
drug in a prolonged plateau release pattern, attaining the minimum 
effective concentration (MEC). Due to the easiness, effectiveness, and 
economically feasible matrix formulations the research and development 
(R&D) scientists in pharmaceutical area recently search for new 
controlled matrices with zero- order release kinetics. The controlled 
release systems were classified according to the mechanism of transport 
as diffusion controlled, swelling controlled and chemically controlled 
systems. The objectives of controlled release systems design is to predict 
the release, elucidate the transport through mathematical models, design 
the delivery system and optimize the release kinetics (2). 
1.2 Fundamental concepts in controlled release: 
In controlled release formulations, the fate of the drug may be 
characterized by a single compartment, which is described by the plasma 
concentration of drug with time. The concentration of drug at receptor 
site versus time reflects the pharmacodynamics or biological response, 
whether it is related to efficacy or adverse reaction. On addition of more 
drugs, the steady state of equilibrium was reached between the plasma 
and the receptor.  
 In controlled release, drug involves the application of physical and 
polymer chemistry to produce a reproducible dosage form to control the 
entry of drug with a required profile. 
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 The delivery rates of controlled release systems may be 
characterized by kinetics of drug and physical processes. A zero-order in 
which the release is constant with time is the ideal one.  
The zero-order release involves the diffusion through semi-
permeable membrane. The membrane is initially loaded with drug to 
obtain an initial burst and followed by steady state diffusion.  
1.3 Oral controlled release dosage forms 
Typical control release is designed to provide constant or nearly 
constant drug levels in plasma with reduced fluctuation via slow release 
of drug over an extended period of time. Controlled release should reduce 
dosing frequency compared to the conventional dosage form (2). 
 The common oral polymeric controlled releases are matrix, 
membrane controlled and osmotic systems. The mechanism of polymeric 
controlled release dosage forms involves drug diffusion though viscous 
gel layer, tortuous channels, or a barrier-drug dissolution via system 
erosion, and drug solution via osmotic pressure. 
 Oral controlled polymeric systems include matrix, reservoir, and 
osmotic systems.  
The matrix systems include: 
1. Hydrophilic, matrix. 
• Swellable.  
• Swellable and erodable.  
2. Hydrophobic matrix 
• Homogeneous (non porous). 
• Heterogeneous (porous).  
i. Inert (monolithic ) 
ii. Erodable. 
iii. Degradable.  
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3. Reservoir systems : 
• Coated beads or pellets  
• Micro-encapsulation. 
4. Osmotic systems  
• Elementary osmotic pumps. 
• Push-pull system. 
• Push-layer system. 
• Push-stuck system. 
5.  Bio-adhesive and buoyant formulations. 
In matrix system the drug is incorporated into the polymer matrix 
by either particle or molecular dispersion (by dissolution). 
In hydrophilic matrix there are two competing mechanisms 
involved in the drug release, Fickian and relaxational release. Not only 
diffusion affects drug release in controlled release from hydrophilic 
matrices, but the erosion followed by polymer relaxation contributes to 
the process of release. 
Drug release behaviour from hydrophilic matrix was expressed by 
a simple semi- empirical formula (58). 
Q = Ktn  
 Where Q = fraction of drug released at time t. 
 K= rate constant related to the characteristics of macromolecule 
network and drug, and n is the diffusion exponent. The value of n was 
indicative of drug release mechanism. For n = 0.5 drug release followed 
Fickian diffusion, which is driven by a chemical potential gradient.  
For n = 1 drug release occurs via relaxational transport associated with 
stresses and phase transition in hydrated polymers. For 1 > n > 0.5 non 
Fickian diffusion results from diffusion and polymer erosion.  
 In relaxation transport in Donald. L (2) reported (Peppas and 
Sahlin) following equation: 
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 Q = K1tn+ K2 t2n  
where K1 and K2 are constants reflecting the relative contribution of 
Fickian and relaxational mechanisms. When the surface area is constant 
(fixed) the value of n should be 0.5 and hence. 
 Q = K1t0.5+ K2 t 
The above equation described the release from hydrophilic matrices. 
 In hydrophobic inert matrix the drug is dispersed throughout the 
matrix. In homogeneous monolithic matrix the release behaviour was 
described by Higuishi equation subject to matrix boundary conditions (2). 
Mt = [ D Cs (2A – C s) t]½   
Where Mt = drug released per unit area at time t. 
A = drug loading per unit volume. 
Cs = solubility  
D = Diffusion coefficient in the matrix phase. 
The above equation was valid on the assumptions: 
a) A pseudo-steady state exists. 
b) Drug particles are small compared to the average distance 
of diffusion. 
c) Diffusion coefficient is constant. 
d) Perfect sink condition exists in the external media  
e) Only the diffusion process exists. 
f) Drug concentration in the matrix is greater than solubility in 
the polymer. 
g) No interactions between drug & matrix. 
When A » Cs the above equation was reduced to  
Mt = [2D AC st]½ and thus the amount of drug released is proportional to 
the square root of time, A, D, & Cs. 
 Release from porous monolithic matrix systems, involves 
penetration of surrounding liquid, dissolution of drug and leaching of 
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drug through the interstitial channels or pores. Volume of channels or 
pores and length of openings in the diffusion process leading to Higuishi 
equation, Donald (2), which is as follows: 
Mt =   ЄCs (2A – ЄCs) Da t  ½   
                                        J 
Where Є and J are the porosity and tortosity of the matrix 
respectively. Da is the diffusion coefficient in aqueous phase. When (A » 
C s).  
Mt = (2Da ACs  t  t ) ½ 
                           J 
The porosity Є is the fraction of matrix that exists as pores or channels 
into which the surrounding liquid can penetrate. It is the total porosity 
after the drug has been extracted. It consists of the  initial porosity, Є a , 
due to air or void space in the matrix before the leaching process begins 
and the porosity created by extracting the drug Є d, and water soluble 
excipients Є ex. 
Є = Є a + Є d + Є ex = Є a + A + Aext 
                                                 ρ     ρ ex 
 
Where ρ is the drug density and ρex and Aex are the density and 
concentration of water soluble exciepents  respectively. 
When no water soluble exciepent was used:  
Є = Є d = A 
                 P 
And hence  
                  Mt =   A   (2 – Cs) Da Cs  t  ½ 
                                            ρ       Jρ 
 
         Mt = A (2Da Cs t) ½ 
                                                          Jρ   
 
In a porous monolithic matrix the release is directly proportional 
to the matrix A.  
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 Ritger and Peppas derived the following equation.  Donald 
reported it, (2) proposing the general release behaviour from 
hydrophobic matrices in the form of slab, sphere and cylinder. As tablets 
were considered as short cylinders, the drug released was calculated 
from:   
          Q = Ktn 
                     
Q = is the fraction released 
K = is constant  
N = diffusion exponent  
In the case of Fickian release the exponent n has value 0.5 for 
slab, 0.45 for sphere & 0.43-0.05 for cylinders .In reservoir polymeric 
systems the common methods for reservoir polymeric system are: 
• Micro-encapsulation of drug particles. 
• Coating of tablets or multi particles. 
• Press coating of tablets.   
A polymeric membrane makes resistance to drug diffusion from 
the reservoir to the sink. Usually the driving force is the concentration 
gradient of active molecules between reservoir and sink .The resistance 
provided by the membrane is the function of film thickness and 
characteristics of both the film and the migrating species in a given 
environment.  The modern method of drug release from the film coated 
dosage forms may be categorized into: 
• Transport of the drug through a network of capillaries filled with 
dissolution media. 
• Transport of the drug through a hydrated swollen film.   
• Transport of a drug through, flaws, crack, and imperfections 
within the coating matrix.  
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Based on Ficks first law of diffusion the release rate of the drug 
from the recovered polymeric system at steady state is given by the 
following equation. 
 
dMt    =   DSK ? C 
  dt              L 
 
Where Mt is the total amount of drug released at time t.  
D   is the diffusion coefficient of the drug.  
S    is the effective membrane or barrier surface area of drug 
diffusion.  
            L    is the diffusion path length (thickness of the film). 
            K is partition coefficient of drug between the barrier and 
aqueous phase    
            ?C is the concentration gradient. 
 In case where D, S, K, L & ?C are constants. The amount of 
drug released as a function of time can be obtained by the following 
equation. 
 Mt = (DSK AC)t   = Kt 
                          L 
Where K = the release rate constant. 
 In osmotic pump systems a tablet core is encased by a semi – 
permeable membrane with an orifice. When the system is exposed to 
body fluid, water will migrate through the semi- permeable membrane 
into the tablet core containing osmotic exciepents and active drug. 
There are usually two osmotic pumps used. 
1. One chamber elementary osmotic pump (EOP). 
2. Two chambers system (e.g. push-pull)  
In both systems the rate of water penetration into the  
systems in terms of volume can be expressed by: 
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 dV      =    Ak (?π - ?P) 
          dt               L 
Where dV = rate of water flow 
             dt 
K     is the hydraulic permeability  
A     is the membrane area  
L     is the thickness  
? π   is the osmotic pressure difference  
? P   is the hydrostatic pressure difference. 
 Due to rigidity of device the volume of the device is constant 
during operation and the amount of drug released at time t is:  
            dM   =  dV   [S] 
             dt         dt 
Where [s] is the drug solubility (2) 
When the hydrostatic pressure difference is negligible  
dM   = kA     ? π [S]  
            dt        L 
 Another system includes ion exchange which contains resins 
composed of water-insoluble cross-linked polymers. These polymers 
contain salt-forming functional groups in repeating positions on the 
polymer chain. The drug is bound to the resin and released by exchange 
with appropriate charged ions that are in contact with the ion exchange 
groups. 
1.4 Materials used for control drug release. 
Materials used for controlled release are divided according to the 
application used into: 
• Matrix  
• Reservoir  
• Osmotic pumps. 
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1.5 Matrices in controlled release drugs: 
 They include hydroxylpropylmethylcellulose (HPMC), 
hydroxylethylcellulose (HEC), Xantham gum, sodium alginate 
polyethylene oxide, cross-linked homopolymers and co- polymers of 
acrylic acid supplied in micronized forms. HPMC grades are classified 
according to the viscosity of 2 % solution, which ranges from 100 to 
100.000 cps. Insoluble resins as carpobols were also used. 
1.6 Materials used for reservoir systems.  
 They include, water insoluble acrylic copolymers and 
ethylcellulose. They are used in organic solutions but recently used as 
aqueous dispersions (2). 
 The acrylic and meth–acrylic acid derivatives include the 
Edragits. 
 Ethylcellulose for film coating available as an aqueous polymeric 
dispersion containing plasticizers was used under the brand name of 
surelease (colorcon) and pseudo - latex dispersion. 
 Coating by acetate phthalate (CAP)  hydroxylpropyl-
methylcellulose phthalate (HPMCP), Eudragit L & S, are all pH–
dependent .They dissolve at pH > 5.5 leading to  release of drug at the 
intestine avoiding the stomach (pH = 1.2 ) . 
 Polymers used for Osmotic pump systems, include cellulose 
acetate containing certain percentage of acetyl content .They are used 
together with other pH-dependent and pH-independent cellulose 
derivatives to form a semi-permeable membrane. Other polymers 
include polyurethane ethylcellulose, poly (ethyl oxide) polymers, 
polyvinylchloride (PVC) and poly vinyl acetate (PVA). 
1.7 Technologies used for oral controlled systems:  
 Oral controlled release systems are in the form of tablets and 
capsules. The technologies used for tablet dosage forms were, 
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spheronization (or pelletization) and film coating of single unit or 
multi-particulates. 
1.7.1 Tablet process technology: 
This technology includes conventional processes of granulation, 
blending, compression and coating. In matrix technologies the pre-
compression is needed because high concentrations of polymers are 
often used (2). 
1.7.2 Spheronization (pelletization) process technology. 
It is done by using microcrystalline cellulose. Pellets or beads or 
spheres were produced, since they minimize the process of dose 
dumping. Usually these pellets or beads have different release rates 
.The basic method of pellets or beads formation include: 
a) Micro-encapsulation. 
b) Spray congealing. 
c) Formation of particles from plastic mass. 
d) Agglomeration. 
1.7.3 Coating technology: 
Coating is by deposition of a uniform membrane of polymer onto 
the surface of substrate as tablet, spheres, pellets, and drug particles.  
 Coating process technology includes: 
• Film coating. 
• Layer coating. 
• Compressed coating. 
The properties of the coating are the function of coating 
formulation as well as coating process variables. 
The equipment used is either coating pan, fluid bed or a rotary 
granulator.   
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1.8 Feasibility assessment of controlled release. 
The feasibility is not economically but rather therapeutically 
dictated by the following parameters as: (2) 
• Physicochemical. 
• Biopharmaceutical. 
• Therapeutic. 
• Overcome physiological constrains. 
1.9 The most important factors in controlled release are: 
1.9.1 Solubility: 
Poorly soluble drugs are usually extended in action due to the 
slow dissolution. However the dissolution kinetics of these drugs is 
non-linear and varies with particle size, surface area, and size 
distribution. The absorption is also extended since the amount of fluid 
available for dissolution is limited. 
1.9.2 Stability: 
Drugs must be stable to pH, enzymes, and flora, through the 
gastro-intestinal tract (G.I.T). 
1.9.3 Lipophilicity / Permeability: 
Absorption of hydrophilic drugs with poor permeability may be 
limited by membrane permeation which varies with the surface area 
and enzymatic activities in different regions of GIT. Changing the 
release rate of such drugs may have little effect on the shape of plasma 
profiles and may even result in deceased absorption (2). 
1.9.4 Elimination t½: 
The philosophy behind the controlled release is the extension of 
the short half life of drugs (2- 6 hr) to longer half life but other factors 
as minimum effective concentration (MEC) , volume of distribution 
and dose, determine the feasibility of controlled release drug . 
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Controlled release may be feasible with one drug while it may be non 
feasible with other drugs of the same half life. 
1.9.5 Therapeutic window: 
The most important criterion of controlled release is the ability to 
maintain plasma levels within therapeutic range with reduced 
fluctuations. For drugs with relatively short half–lives, the lower the 
minimum effective concentration (MEC) is, the more likely it is to 
achieve prolonged drug exposure above MEC with controlled release 
systems, but with fluctuations of plasma level at steady state. This is 
undesirable in narrow therapeutic-index drugs. 
1.9.6 First pass metabolism: 
Drugs with saturable first pass metabolism (hepatic or gut), bio-
availability will be decreased due to the systemic input from controlled 
release systems limiting the chance of success.   
1.9.7 Pharmacokinetic, pharmacodynamic relationship (PK/PD) 
relationships: 
Relationship between drug concentration (C) and pharmacological 
effect (E) is described by a sigmoid   E max model. A shallow E-C 
relationship indicates a slight response E in high concentration which 
gives no rational controlled release development (2). 
Controlled release of drugs is to release a drug at specific target, to 
act either systemically or locally. The objective of controlled release of 
drugs is to modify the normal behavior of drugs molecules in a 
physiological environment. It can lead to the followings: 
1- Sustained drug action at a predetermined rate by maintaining a 
constant effective drug level in the body with concomitant 
minimizing of undesirable side effects associated with a saw tooth 
kinetic pattern. This will give a constant drug release at specific 
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period of time attaining a constant blood level. More specifically it 
is a modification of drug that prolongs its therapeutic activity (2). 
2- Localization of drug action in the diseased tissue or organ, to avoid 
the activity of drug at specific target due to its untoward properties. 
3- Targeting drug action by a carrier to deliver drug to a particular 
target (3). 
Locally acting drugs sometimes target a specific part of gastro-
intestinal tract (G.I.T). Metronidazole and Albendazole drugs were 
incorporated in guar gum to give a colon targeted formulation (4). 
 Oral controlled release dosage forms are developed to specific 
targets with improvement of pharmacological action and reduced toxic 
side effects (5). Despite of overcoming patient’s compliance by 
controlled release formulations; new technology development in tablet 
production is established. The decrease of incidence of adverse drug 
reaction is also achieved. 
 Hydrophilic matrices containing swelling polymers are referred to 
as hydro gel matrices; swelling controlled release systems or hydrophilic 
matrix tablets (6). A number of polymers have been investigated for 
development of in situ gel forming systems due to their ability to control 
the release of drug from aqueous media due to its physical property of 
swelling or cross-linking (7, 8, 9). 
 Hydrophilic matrices include: carboxymethylcellulose sodium 
(CMC), methylcellulose (MC), hydroxypropylcellulose (HPC), and 
hydroxyethylcellulose (HEC), polyethylene oxide (PEO), 
polyvinylpyrrolidone (PVP), polyvinyl acetate (PVA), 
carboxypolymethylene (CPM), alginic acid, gelatin and natural gums 
(10). These matrices can be formed into a tablet by direct compression or 
wet granulation containing the active drug with the hydrophilic matrix. 
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 Various designations for controlled release drugs are called: Smart, 
Targeted, Intelligent, Novel and Therapeutic controlled release dosage 
forms. 
 Most of the controlled release systems fall in the category of 
passive programmed, in which the release is pre-determined and is 
irresponsive to the eternal biological environment. 
Controlled release dosage forms also reduce fluctuations in plasma 
drug level by slowing down the absorption rate due to slower drug release 
from the system. 
 Enteric coated formulations comes under the category of controlled 
delivery systems in which the release of drug in the stomach is avoided 
and release of drug takes place in the intestinal region for absorption. 
Polymers have gained an important role in the pharmaceutical industry as 
drug encapsulates and vehicles of drug carriage protecting or controlling 
the drug release (11). 
1.10 Advantages of controlled release: 
A- Delivery to the required site. 
B- Delivery at the required rate. 
C- Reduce the danger of overdose or side effects. 
D- More efficient dosage. 
E- Reduce dose frequency. 
F- Reduce fluctuations in circulating drug level. 
G- Decrease patient compliance. 
H- Avoidance of night- time dosing. 
I- More uniform effect. 
J- Reduction of GIT irritations. 
1.11 Disadvantages of Controlled release Drugs: 
A- Cost is very high. The high cost of controlled release dosage forms 
must again be taken into account when the advantages and 
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disadvantages of the drug formulated in controlled release manner 
is being considered. 
B- Unpredictable in vitro in vivo correlation. Dose dumping (12) is a 
phenomenon whereby large quantity of medication in a controlled 
release formulation is rapidly released introducing potentially toxic 
quantities of drug into systemic circulation. This has been reported 
for vasodilators. Reduced drug absorption is an intrinsic hazard 
since the dose is partially released at the stomach especially in 
matrix controlled release drugs. And apart from the gastric 
residence time this fraction of released drug is at a distal region to 
the optimum absorptive region of the intestine which is considered 
as absorption window and may give rise to unsatisfactory drug 
absorption in vivo despite the excellent release characteristics for in 
vitro. 
C- Dose dumping, because sometimes controlled release dose is 16 
times the normal dose which may cause toxic side effects if 
chewed. 
D- Reduced potential for dosage adjustment and increased potential 
for 1st pass clearance and hence poor availability. Reduced 
potential for dosage adjustment is a major disadvantage of some 
controlled release products. And this should be considered when 
preparing controlled release formulations. 
Reduced potential for dosage adjustment is a major disadvantage of 
some controlled release products. And this should be considered 
when preparing controlled release formulations. Hepatic 
metabolism is a saturable process. After oral dose the drug reaches 
the liver via the portal vein in far greater concentrations than 
normally observed in systemic circulation. In fact the levels may be 
high enough to exceed the capacity of hepatic metabolizing 
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enzymes. Thus the higher the oral dose the greater is the possibility 
of saturating hepatic drug metabolizing enzymes. Conversely the 
smaller the dose or slower the release of the drug from the 
formulation, the smaller is the possibility of saturating fist pass 
metabolism. The potential for reduced drug availability due to first 
pass metabolism is therefore greater with controlled release 
formulations than with conventional dosage forms. Hepatic 
metabolism is a saturable process. After oral dose the drug reaches 
the liver via the portal vein in far greater concentrations than 
normally observed in systemic circulation. In fact the levels may be 
high enough to exceed the capacity of hepatic metabolizing 
enzymes. Thus the higher the oral dose the greater is the possibility 
of saturating hepatic drug metabolizing enzymes. Conversely the 
smaller the dose or slower the release of the drug from the 
formulation, the smaller is the possibility of saturating fist pass 
metabolism. The potential for reduced drug availability due to first 
pass metabolism is therefore greater with controlled release 
formulations than with conventional dosage forms. 
E- Effective drug release is affected by gastro intestinal residence 
time. 
1.12 Controlled release Input factors: 
A- A sound development / design manufacture base. 
B- Pre-formulation research data. 
C- Rational dosage form design. 
D-  Formulation of reliable and stable system. 
E-  A precise, reproducible manufacturing scheme. 
F-  A sensitive product quality control. 
G- Qualified and responsible personnel in management and, R&D, 
quality control, production, and services (12). 
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1.13 Controlled release drugs outputs: 
A- Effectiveness. 
B- Safety. 
C- Reliability and stability. 
D- Pharmaceutical elegance. 
E- Appearance and organoleptic properties. 
F- Convenience. 
G- Ease of use. 
H- Dosing frequency. 
I- Consumer acceptance. 
1.14 Evaluation of controlled release preparations: 
1.14.1In vitro 
A- Dissolution rates. 
B- Tablet hardness for polymer matrix. 
C- Porosity of tablets. 
D- Weight variations. 
E- Content uniformity. 
F- Friability. 
1.14.2 In vivo 
A- Pharmacological response. 
B- Clinical response. 
C- Blood level data C max, t1/2 AUC. 
D- Urinary excretion. 
E- Kinetic studies according to 1st, Zero, or Higuishi equations. 
F- Toxicity studies. 
1.15 Regulatory Assessment: 
Demonstration of safety and efficacy of controlled release drugs by 
(13). 
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A- Controlled clinical studies required to demonstrate the safety of and 
efficacy of the drug in controlled release formulation. 
B- Drugs that are approved to be safe in controlled release forms, data 
are required to establish bio-availability compared to an approved 
controlled release product of the same origin. 
C- A single dose bio-availability is necessary and acceptable in case of 
study the amount of absorbed, in fasting. 
D- No dose dumping. 
E- The formulation of controlled release should provide consistent 
pharmacokinetics performance between individual forms. 
F- In vitro and in vivo methods should be correlated in controlled 
release products. 
1.16 Fabrication techniques: 
There are different methods of fabrication of controlled release 
drugs by: 
A- Increasing of the particle size of the drug. 
B- Embedding the drug in a matrix. 
C- Coating. 
D- By dry complexes. 
E-  Using ion exchange resin. 
Matrix tablets for controlled release were supposed to have 
superior benefits to the other methods of preparation. Direct compression 
(DC) method is time saving less labor, non-tedious, with less machinery 
required. This will save money and time. One method of formulating 
controlled release tablets is by incorporation of a drug in a hydrophilic 
matrix which controls the rate of release (14, 15). The use of HPMC was 
illustrated in mathematical models as controlled release matrices (16). 
Sustained release tablets are made by incorporation of natural 
and/or synthetic polymers to import the sustained release property to the 
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formulation. The polymers are: Wax matrices, Hydrogenated oils, fatty 
acids and alcohols esters of fatty acids, Metallic soaps; which all act as 
coat or entrap to limit the solubility of the drug and prolong its release. 
Slightly soluble drugs are more susceptible to prolonged action to provide 
drug level within the therapeutic range 8-12 hours with a single dose 
rather than a short action. This prolonged release is affected by gastric 
motility whether delayed or enhanced since the gastro-intestinal tract 
motility is not uniform. 
1.17 Matrix tablet formulation: 
 Several hydrophilic patented matrices have been in use as synchron 
technology (17) and hydrodynamically balanced systems (18). Addition 
of water to hydrophilic matrix activates the release of drug. The 
formation of hydrophilic base gel layer around the tablet after immersion 
in water makes controlled release, which is effective by gel diffusion 
barriers to control erosion of tablets (10). 
Acacia alone as a prolonged release matrix was found to be 
ineffective as a controlled release matrix which was due to short chain 
molecules of acacia. The three layer matrix tablet also showed no 
controlled release. A combination of gum Arabic and guar gum was 
found to be of similar controlled action as the polysaccharide blend of 
guar gum and naturally occurring gums as gum Arabic. 
 The effect of formulation and drug release behavior from different 
hydrophilic matrices can be summarized in the following points. 
The matrix building material with fast polymer hydration 
capability is the best choice to use in a hydrophilic matrix tablet 
formulation. An adequate polymer hydration rates my cause premature 
diffusion of the drug and disintegration of the tablet owing to fast 
penetration of water. 
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The amount of hydrophilic polymer in tablet formulations was 
reported to have a marked influence on the disintegration time and 
dissolution of the tablet. The disintegration time was extended as polymer 
content increased. The release rate of drug was decreased when the 
proportion of polymer was increased but differed quantitatively with 
different drugs and different matrix building materials. Slower hydration 
polymers can be used at higher concentration level to accelerate gel 
formation or reserved for water insoluble drug (s). 
Generally reduced particle size of hydrophilic polymer ensures 
rapid hydration and gel formation, leading to good controlled release .The 
impact of polymer particle size on the release rate is formulation 
dependant, but may be obscured in some cases. The particle size of a 
drug, within a normal size range, my not significantly influence the drug 
release from the matrix tablet. Extremes of drug particle size may affect 
release rate of the drug. 
Viscosity characteristics of the polymers are of real importance in 
determining the final release properties of the matrix tablet. Generally the 
drug release rate is slower for a higher viscosity grade polymer. 
Commonly water soluble excipients in the matrix tablets can 
increase drug release. However, addition of water soluble materials may 
achieve slower rate by increasing viscosity of the gel through interaction 
with hydrophilic polymers or by competition with matrix materials for 
water. When water insoluble non-swellable excipient(s) or drug(s) is used 
in the matrix system stress cracks can occur upon immersion in water 
because of the combination of swelling or non-swelling components on 
the tablet surface. 
For some hydrophilic matrix building materials, pH may affect the 
viscosity of the gel which forms on the tablet surface and its subsequent 
rate of hydration. Under acidic conditions carboxypolymethylene and 
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Sodium carboxymethylcellulose have little or no retarding effect on the 
drug release rate. Gelatin forms gels of higher viscosity in acidic media 
and is more effective in retarding drug release as compared to basic 
media. 
No conclusions have been drawn from the effect of compression 
force on drug-release behavior in hydrophilic matrix materials. However, 
tablet size and shape can significantly influence the drug-release kinetics. 
The drug can be incorporated into fat-wax granulations by spray 
congealing in air, blend congealing in an aqueous media with or without 
the aid of surfactants, and spray-drying techniques. In the bulk congealing 
method a suspension of drug and melted fat-wax is allowed to solidify 
and is then comminuted for sustained-release granulations. The mixture 
of active ingredients, waxy material(s), and filler(s) also can be converted 
into granules by compacting with a roller compacter, heating into a 
suitable mixer such as a fluidized-bed and steam-jacketed blender, or 
granulating with a solution of waxy material or other binders. Fat-wax 
granulations containing drug obtained from all of the above processes 
may be compressed to form tablet cores or directly compressed to a final 
tablet form with sustained release properties. 
The drug embedded into a melt of fats and waxes is released by 
leaching and / or hydrolysis as well as dissolution of fats under the 
influence of enzymes and pH change in the gastro-intestinal tract. Enteric 
materials such as cellulose acetate phthalate, polyvinyl acetate phthalate, 
methacrylate copolymer, Zien and shellac may be used to prepare matrix 
tablets with somewhat a similar drug-release mechanism. In general the 
primary constituents of fat wax matrix are fatty acids and /or fatty esters. 
Fatty acids are more soluble in an alkaline rather than an acidic medium. 
Fatty esters are more susceptible to alkaline catalysed hydrolysis than to 
acidic catalysed hydrolysis. The surface erosion of a fat-wax matrix 
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depends upon the nature and percent of fat-wax and extenders in a matrix. 
Other factors such as drug particle size and drug concentration affect 
release of the drug from the matrix system. The addition of surfactants to 
the formulation can also influence the drug release rate and the proportion 
of the total drug incorporated into a matrix. Polyethylene, ethylcellulose, 
and glycerylesters of hydrogenated resins have been added to modify the 
drug-release pattern. 
 Sustained-release tablets based upon an inert compressed plastic 
matrix were first introduced in 1960 and have been used extensively. 
Plastic matrix tablets have delayed action because the dissolved drug has 
to diffuse through a capillary network between the compacted polymer 
particles. Commonly used plastic matrix beds are polyvinyl chloride, 
polyethylene, vinylacetate /vinyl chloride copolymer, vinylidine chloride 
/acrylonitryle copolymer, acrylate methacrylate copolymer, 
ethylcellulose, celluloseacetate, and polystyrene. Plastic matrix tablets in 
which the active ingredient is embedded in a tablet with coherent and 
porous skeletal structure can be easily prepared by direct compression of 
drug with plastic material(s) provided that the plastic material can be 
comminuted or granulated to the desired particle size to facilitate mixing 
with drug particle or granulate for compression into tablets(10) 
1.18 Embedding process: 
Embedding process may be accomplished by: 
1- Mixing and kneading of drug and plastic material with the solution 
of the same plastic material or other binding agent in an organic 
solvent and then granulated. 
2- Dissolution of drug in organic solvent and granulated upon 
evaporation of solvent. 
3- Using latex or pseudo-latex as granulating fluid to granulate the 
drug and the plastic mass. 
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 Drug release from the inert plastic matrices is affected by varying 
formulation factors such as: 
A- Matrix material 
B- Amount of drug incorporated in the matrix. 
C- Drug solubility in the dissolution media and in the matrix. 
D- Matrix additives. 
E- Release media. 
 Since the mechanism of controlling the drug release in the plastic 
matrix is the pre structure of the matrix, any formulation factors affecting 
the release of a drug from the matrix may be a consequence of their 
primary effect on apparent porosities and tortuosities of the matrices.  
1.19 Release factors  
Release factors can be summarized as follows: 
A- The release rate increases as the solubility of the drug increases, but 
there seems to be no direct relationship between the two variables. 
B- The release rate increases as the drug concentration increases. An 
increase in release rate cannot be explained on the basis of 
increasing matrix porosity. Rather it has been attributed to change 
in matrix tortuosity with drug concentration. And to decrease 
diffusion resistance by shortening the length of capillary joining 
any two drug particles. 
C- It is possible to modify the release rate by inclusion of hydrophilic 
or hydrophobic additives to the matrix .The release of sparingly 
soluble substance can be increased by addition of physiologically 
inert but readily soluble material such as polyethylene glycol, 
sugars, electrolytes, and urea. The decrease in the release rate on 
the addition of hydrophobic substance may be due to decreased 
wettability of the matrix.  
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D- The release rate from plastic matrix tablets could be decreased by 
exposure to acetone vapor without changing the release 
mechanism. The extent of reduction is dependent on the amount of 
acetone absorbed. 
E- The release rate increased as the particle size of the matrix material 
increased and as the particle size of the drug decreased. 
F- Increasing compaction pressure up to the full consolidation point 
tends to decrease the pore formed among the polymer particles, 
resulting in slower drug-release. 
 The optimization of the efficacy of an active constituent often 
involves its availability at site of action. This gives the pharmaceutical 
companies a major concern to new drug delivery systems. In sustained 
release forms the release kinetics are not controlled but in controlled 
release forms the release kinetics can be adjusted by the design of the 
system, and can result in a constant plasma level within the therapeutic 
margin between the threshold of efficacy and toxicity (41). 
1.20 Non-steroidal anti-inflammatory drugs (NSAIDS): 
There are more than 50 different non –steroidal anti-inflammatory 
drugs (NSAIDS) on the market (42) as the NSAIDS include a variety of 
different chemical class. They have the major effects: Anti-inflammatory, 
analgesic and anti-pyretic effects. 
All the three effects are mediated through the inhibition of cyclo-
oxygenase and hence prostaglandins and thromboxanes .Cyclo-oxygenase 
(Cox) has two types Cox1 & Cox2. Cox1 is a consecutive enzyme 
expressed in most tissues including blood platelets and tissue 
homeostasis. Cox2 is induced in the inflammatory cells and it is believed 
to be the enzyme that produces the prostanoid mediators of inflammation. 
Most NSAIDS inhibit both Cox1 & Cox2 (43). 
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 Non–steroidal anti-inflammatory agents act by inhibition of 
prostaglandin at one or more points in the indo-peroxide biosynthetic 
ways and desensitize blood vessels to the permeability effects of other 
mediators of inflammation (44). This inhibition of prostaglandin leads to 
the anti-inflammatory effects of NSAIDS. The bad side effects of the 
abdominal irritation is due to the inhibition of the cyto-protective effect 
prostacyclin on gastric mucosa (45). NSAIDS are generally weak acids, 
highly protein bound, and those with a higher pka have a longer duration 
of action. 
 Numerous publications had been written about the release of non-
steroid anti-inflammatory drugs to treat rheumatoid pains rheumatoid 
arthritis and osteoarthritis (45) 
1.21 Diclofenac Sodium: 
Diclofenac sodium is one of the most popular drugs which have 
superior use over other steroidal anti-inflammatory drugs. Diclofenac 
Sodium as a non-steroidal anti-inflammatory drug is used for relief of 
pain and inflammations in various conditions as: 
A- Musculo-skeletal and joint disorders as rheumatic pain. 
B- Peri-articular disorders such as persitis and tendonitis. 
C- Soft tissue disorders such as sprains and strains. 
D- In painful renal colic. 
E- Acute gout. 
F- Dysmenorrhea. 
G- After surgical operations. 
 The adverse side effects include gastrointestinal disturbances, 
which may lead to peptic ulcer and severe gastro-intestinal bleeding. Epi-
gastric pain, nausea, vomiting and diarrhea .Other side effects include 
hypersensitivity, tinnitus, depression, drowsiness and insomnia.  
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Diclofenac sodium is a Sodium salt of 2-[(2,6-dichlorophenyl) 
amino]phenyl] acetate. Diclofenac Sodium is practically insoluble in 
acidic solution (pka =4.0), but it dissolves at the intestine medium and 
water. Its Structural formula is C14H10CL2N NaO2. 
1.21.1 Mechanism of action of Diclofenac sodium: 
 The mechanism of anti-inflammatory antipyretic analgesic action is 
through inhibition of prostaglandin synthesis by inhibition of cyclo-
oxygenase (Cox). Diclofenac inhibit lipo-oxygenase pathway thus 
reducing the formation of leukotrienes. There is also speculations that 
Diclofenac may inhibits phospholipase A2. Inhibition of Cox also 
decreases prostaglandins in the epithelium of the stomach making it more 
sensitive to corrosion by gastric acid. 
1.21.2 Pharmacodynamics: 
Diclofenac acts by the inhibition of prostaglandins biosynthesis 
which plays an important role in the causation of inflammation, pain, and 
fever. In rheumatic diseases, the anti-inflammatory and analgesic 
properties of Diclofenac elicit a clinical response characterized by 
marked relief from signs and symptoms such as pain at rest, pain on 
movement, morning stiffness and swelling of the joints.  
1.21.3 Pharmacokinetics: 
 Judged by renal recovery of Diclofenac and its metabolites, the 
same amount of Diclofenac is released and absorbed from Diclofenac 
slow release and enteric coated tablets (46). Presumably due to a rate–
dependent first pass effect, the systemic availability of Diclofenac from 
Diclofenac slow release is on the average of about 82 to 84% of the same 
dose administered as enteric-coated tablets. As a result of a slower release 
of the active substance from Diclofenac slow release, peak concentrations 
attained are lower than those achieved following the administration of 
enteric coated tablets. Mean peak concentration of 0.5 µg/ml or 0.4 µg/ml 
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(1.6 or 1.25 µmol/liters) are reached on the average about four hours after 
ingestion of a slow release tablet of 100 mg or 75 mg .On the other hand 
mean plasma concentrations of 13 ng/ml (40 nmol/litre) can be recorded 
at 24 hours after administration of Diclofenac slow release 100 mg (46). 
Food has no clinically relevant influence on the absorption and systemic 
availability of Diclofenac (Voltaren SR) (46). 
 Since about half the active substance is metabolized during its first 
passage through the liver (first pass effect). The area under the 
concentration curve (AUC) is about half as large following oral or rectal 
administration as it is following a parenteral dose of equal size. 
Diclofenac is bound to serum protein at a rate of 99.7%, chiefly albumin 
99.4% (46). The total systemic clearance of Diclofenac in plasma is 263 + 
56 ml/min (mean value +SD) The terminal half life is 1-2 hours after 
intravenous or oral administration of conventional dosage forms. 
Pharmacokinetic behavior remains unchanged following repeated 
administration. No accumulation occurs provided the recommended 
dosage intervals are observed. Trough concentrations are around 22ng/ml 
or 25 ng/ml (70 nmol/litre or 80 nmol/litre) during treatment with 
Diclofenac slow release 100 mg once daily or 75 mg twice daily. 
 The bio-transformation of Diclofenac involves partly 
glucuronidation of the intact molecule but mainly single and multiple 
hydroxylations followed by glucuronidation. About 60% of the 
administered dose is excreted in the urine in the form of metabolites as 
one of these two processes. Less than 1% is excreted as unchanged 
substance; the remainder of the dose is eliminated as metabolites through 
the bile in the faeces. No relevant age-dependent differences in the drug’s 
absorption, metabolism, or excretion have been observed. In patients 
suffering from renal impairment, no accumulation of the unchanged 
active substance can be inferred from the single-dose kinetics where 
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applying the usual dosage schedule. At a creatinine clearance of < 
10ml/minute, the theoretical steady-state plasma levels of metabolites are 
about 4 times higher than in normal subjects. However, the metabolites 
are ultimately cleared through the bile. In the presence of impaired 
hepatic function (chronic hepatitis, non-decompensated cirrhosis) the 
kinetics and metabolism of Diclofenac are the same as in patients without 
liver disease (46)  
1.21.4 The indications of Diclofenac are: 
A- Inflammatory and degenerative forms of rheumatism: rheumatoid 
arthritis; ankylosing spondylitis osteo-arthrosis and 
spondylarthritis. 
B- Painful syndromes of the vertebral column. 
C- Non-articular rheumatism. 
D- Painful post-traumatic and post-operative inflammation and 
swelling. 
E- Painful and/or inflammatory conditions in gynecology e.g. primary 
dysmenorrhea or adnexitis. 
1.21.5 Contra-indications: 
A- Hepatic ulcer 
B- Hypersensitivity to the active substance. 
C- Asthmatic patients, urticaria, or acute rhinitis are precipitated by 
acetylsalicylic acid or by other drugs with prostaglandin-synthetase 
inhibiting activity.  
1.21.6 Adverse reactions 
The adverse reactions include the following: 
1- Gastro-intestinal tract 
2- Central nervous system 
3- Skin 
4- Kidney 
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5- Liver 
6- Blood 
7- Hypersensitivity 
8- Other organ systems 
1.21.7 Action on gastro-intestinal tract: 
 Occasional: epi-gastric pain, other gastro-intestinal disorders such 
as nausea, vomiting, diarrhea, abdominal cramps, dyspepsia, flatulence, 
anorexia. 
Rare: gastro-intestinal bleeding haemato-emesis, Melina, peptic 
ulcer with or without bleeding or perforation, bloody diarrhea (46). 
In isolated cases: lower gut disorders such as non-specific 
hemorrhagic colitis and exacerbation of ulcerative colitis or Crohn’s 
proctocolitis; aphthous stomatitis; glossitis; esophageal lesions; and 
constipation. 
1.21.8 Action on central nervous system: 
 Occasional: headache, dizziness, vertigo and rare drowsiness. In 
isolated cases: disturbance of sensation, including paraethesia, memory 
disturbance, disorientation, disturbance of vision (blurred vision, 
diplopia), impaired hearing, tinnitus, insomnia, irritability, convulsions, 
depression, anxiety, nightmares, tremor, psychotic reactions, taste 
alteration disorders . 
1.21.9 Action on skin: 
 Occasional: rashes or skin eruptions. Rare urticaria. 
In isolated cases: bullous eruptions, eczema, erythema multiform, 
Stevens-Johnson syndrome, Yell’s syndrome  
(Acute toxic epidermolysis), erythroderma (exfoliative dermatitis), loss of 
hair, photosensitivity reactions, purpura, including allergic purpura. 
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1.21.10 Action on kidney: 
In isolated cases: acute renal failure, urinary abnormalities such as 
haematuria, proteinuria (46). Interstitial nephritis, nephritic syndrome, 
and papillary necrosis. 
1.21.11 Action on Liver: 
Occasional: elevation of serum aminotransferase enzymes (SGOT, 
SGPT).  
Rare: hepatitis with or without jaundice. 
In isolated cases: fulminant hepatitis. 
1.21.12 Action on Blood: 
In isolated: thrombocytopenia, leucopenia, anemia  
(Hemolytic anemia) agranulocytosis. 
1.21.13 Hypersensitivity: 
Rare: hypersensitivity reactions such as asthma, anaphylactic or 
anaphlactoid systemic reactions including hypotension. Other organ 
systems, rare oedema. In isolated cases impotence, palpitation, chest pain 
hypertension. 
1.21.14 Precautions: 
Close medical surveillance is imperative in patients with symptoms 
indicative of gastro-intestinal dis-orders, with a history of suggestive 
gastro-intestinal ulceration, with ulcerative colitis or with Cronhn disease 
as well as in patients suffering from severe impairment of hepatic 
function. 
Gastro-intestinal ulceration or bleeding of Diclofenac is more 
serious in elderly. They can occur any time during treatment with or 
without warning symptoms or a previous history. In this case of receiving 
Diclofenac the treatment should be stopped.  
Owing to the importance of prostaglandins for maintaining renal 
blood flow particular caution should be made in patients with impaired 
cardiac or renal function, in the elderly, in patients being treated with 
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diuretics and in those with extra-cellular depletion e.g. in pre or post 
operative phases in major surgical operations . So monitoring of renal 
function is essential in Diclofenac usage. Diclofenac should be used with 
the lower effective dose in elderly and lower body weights. 
As with other non-steroidal anti-inflammatory drugs elevation of 
one or more liver enzymes may occur with Diclofenac. During prolonged 
treatment with Diclofenac monitoring of hepatic function tests persist or 
worsen, if clinical signs or symptoms consistent with liver disease 
develop, Diclofenac should be discontinued .During prolonged treatment 
with Diclofenac as with other anti-inflammatory agents blood counts are 
recommended (46). 
1.21.15 Pregnancy and lactation: 
 During pregnancy Diclofenac should be employed only for 
compelling reasons and only in the lowest effective dose, particularly in 
the last 3 months of pregnancy owing to the  
possibility of uterine inertia and /or premature closure of the ductus 
arteriosus. Following oral doses of 50 mg of Diclofenac administered 
every 8 hours, the active substance pass into the breast milk, but in small 
quantities with negligible effects on the infants. 
1.21.16 Effect on ability to drive: 
While taking Diclofenac patients experiencing dizziness or central 
nervous system disturbances should avoid driving vehicles (46) 
1.21.17 Interactions: 
When Diclofenac is given with digoxin plasma concentration was 
elevated. Various non-steroidal anti-inflammatory agents are liable to 
inhibit the activity of diuretics. Concomitant treatment with potassium 
sparing diuretic may be associated with increased serum potassium levels. 
Thus making it necessary to monitor the latter. Concomitant 
administration of systemic no steroidal anti-inflammatory agents may 
increase the occurrence of side effects. 
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Although clinical investigation does not appear to indicate that 
Diclofenac has an influence on the effect of anticoagulants. There are 
isolated reports of an increased risk of hemorrhage with the combined use 
of Diclofenac and anti-coagulant therapy. Therefore close monitoring of 
such patients is recommended. As with other non-steroidal anti-
inflammatory agents, Diclofenac in a high dose can temporarily inhibit 
platelet aggregation. 
Clinical studies have shown that Diclofenac can be given together 
with oral anti-diabetic agents without affecting their clinical effect (46). 
Caution should be exercised when non-steroidal anti-inflammatory 
drugs are administered less than 24 hours before or after treatment with 
methotrexate , since the blood concentration of methotrexate may rise and 
toxicity of this substance may be increased. Increase nephrotoxicity of 
cyclosporine may occur through effects of non-steroidal anti-
inflammatory drugs on renal prostaglandins (46).  
1.21.18 Dosage and administration: 
The administration of Diclofenac controlled slow release is 
according to the case of treatment. The dose is 100-150 mg administered 
as single or divided dose to be taken with liquid preferably at meal times. 
1.21.19 Overdose: 
Management of acute poisoning with non-steroidal anti-
inflammatory agents consists of supportive and symptomatic measures. 
There is no clinical picture resulting of overdose of Diclofenac. In case of 
overdose treatment may be initiated by gastric lavage and activated 
charcoal. Supportive and symptomatic treatment should be given for 
complications such as hypotension, renal failure, convulsions, gastro-
intestinal irritation and respiratory depression. Specific therapies such as 
forced dieresis, or dialysis is of no help in eliminating non-steroidal anti-
rheumatic agents because of their high protein binding rate and extensive 
metabolism. 
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Chapter II 
Rationale and Objectives 
2.1 Rational and objectives: 
 Various matrices for controlled delivery systems were developed, 
from the simple matrix, coated pellets, microcapsules, ion exchange 
resins, hydrogels, to osmotic pumps (47) 
This study is carried out to preparation of different combinations of 
hydrophilic, hydrophobic, natural and semi-synthetic gums as controlled 
release matrices, and studied the in vitro release profiles, using different 
simulated physiological pHs similar to that of GIT pHs {1-8} (47). The in 
vitro drug pattern was studied, to extrapolate the effectiveness of these 
combinations as drug delivery systems. The controlled systems by 
coating process is a tedious long process, so the aim is to develop a new 
matrix delivery systems with controlled action to overcome this problem. 
We intended to use our resources as gum Arabic and guar gum for 
formulation. 
 Hydrophilic matrix hydroxypropylmethylcellulose (HPMC) (6), 
hydrophobic matrix acrylic acid and methacrylate derivatives (Eudragit 
L100)(48) natural gums (guar gum and gum Arabic), combination of 
semi-synthetic and natural gum (Xanthan gum plus gum Arabic) (49) all 
in different proportions were used as controlled release matrices.  
In vitro release profiles were studied for the matrix controlled release 
Diclofenac sodium tablets (MT20, MT33, MT34) to see the similarity of 
these delivery systems compared to Voltaren retard (V.R) in gradient pHs 
(1.2, 2.1, 4.2, 5.5, 6.5, 6.7, & 7.2) (1). The drug release kinetics was also 
evaluated.  
The study of controlled release Diclofenac sodium from different 
matrices has a scientific and economical value.  
2.2 General objectives of study: 
2.2.1- Manufacture a controlled release Diclofenac with similar attributes 
of the enteric controlled release brands. 
The rate of absorption was calculated from the following 
parameters Cmax, Tmax, for Voltaren retard and MT33. The control 
(Diclofenac sodium from Novartis®) was compared with MT33.  
 The mean residence time MRT, the area under the moment 
concentration curve to infinity, and area under the curve to infinity were 
calculated. 
The clearance of the drug from the body was also calculated from 
the dose over the area under the curve to infinity. (53). D/AUC0-∞ 
Cmax, Tmax were obtained from the data or the plot of the concentration 
versus time. The standard (Voltaren retard) was compared with the 
sample MT33.  
A plot of AUC against time on semi-log paper was made and the 
AUC24 was calculated the trapezoid method. 
AUC24    = ∑ (C1+ C2) (t2 - t1) + (C2 +C3) (t3-t2) + etc 
For AUC0-∞ was calculated from: 
AUC0-∞ = ∑ AUC24 + {Clast (reading24)} / Kel (54). 
The rate of elimination = (Lncon at 12 hrs – Lncon at 24hrs)/time12 hour. 
AUMC24 = { ( C1X t1+ C2Xt2)/2}X(t2-t1) etc (55) 
AUMC0-∞ = AUMCt + (Clast24 X t)/Kel + Clast/(Kel)2 
T1/2 was calculated from Ln 2 over the rate of elimination 
T1/2 = 0.693/Kel (mean) (56). 
The mean residence time MRT was calculated from equation 
MRT = AUMC0-∞/AUC0-∞. 
Absorption rate = Cmax/AUC0-∞ 
Elimination rate constant was obtained from the plot of 
concentration against time on a semi-log paper at terminal phase to obtain 
Kel . 
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The slope of θ  
Slope = Kel 
The elimination rate constant was determined as the slope of the 
linear regression of the Ln transformed plasma concentration versus time 
data in the terminal phase of the plasma concentration curve. 
3.4.10 Statistical analysis: 
Statistics using p-value was used to assess the differences between 
the pharmacokinetic parameters of controlled release matrix (MT33) 
compared to Diclofenac sodium from Novartis®. To evaluate the Cmax, 
Tmax AUC0-t, AUMC0-t, AUC0-∞, AUMC0-∞, Kel, T1/2, Cmax/AUC0-t student-
test was used to compare the two means at 95% confidence intervals of 
the data or the Ln value of the non uniform data using SPSS software ver 
10.  
3.4.11 validation of analytical method: 
The analytical method of high performance liquid chromatography 
using the above specified portions of buffer, and C18 column was 
validated for precision (SD + 0.42), accuracy (average recovery 
100.36%), specificity (Percentage agreement 105.32%), linearity (within 
0.2 µg/ml-1 µg /ml) and limit of detection (LOD) was 10 ng /ml.   
3.5 Quantitative analytical techniques: 
3.5.1 Instrumentation: 
Analysis of the matrices (MT20, MT33, and MT34) was performed 
using high performance liquid chromatography (HPLC) system 
consisting of Knauer K1001 isocratic pump and K-2501 ultra-violet 
visible spectrophotometer Knauer Germany at 254 nm. A rheodyne 
injection valve with 20 µl fixed filling loop. The analytical columns were 
C8, Eurosphere-100 (5 µm) 4.6 mm ID x 250mm with pre-column, and 
C18, Eurosphere-100 (5 µm) 4 mm ID x 100 mm. Both systems were 
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coupled with degasser Knauer and Eurochrome 2000 software for HPLC 
analysis. 
3.5.2 HPLC Conditions: 
The mobile phase was degassed phosphate buffer ((0.1% W/V 
solution orthophosphoric acid and 0.16% sodium 
dihydrogenorthophosphate) adjusted at pH 3.5 (34 volumes) plus (66 
volumes) methanol (57). 
3.5.3 Sample preparation and standards: 
The stock solution of the three matrices (MT20, MT33, MT34) 
were prepared by crushing of 10 tablets of each sample and the average 
amount of 100 mg was taken to it 0.1% orthophosphoric acid and 0.16% 
sodium dihydrogenorthophosphate)/methanol (34:66 V/V) solution 
(mobile phase), was added in a 100 ml measuring flask. The internal 
standard, Ibuprofen, was added (1 mg/ml). The mixture was stirred for 
about 15 minutes, filtered through Whatman No1 filter paper and 
adjusted to volume. The standard Diclofenac sodium was treated in the 
same manner. All standard and samples were 1mg/ml concentration. 
Giving the same overlapped peaks, Ibuprofen was replaced by 
propylparaben as internal standard. 
3.5.4 Assay: Sample analysis: 
 20 µl of each sample and standard were injected each time. 
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3.6 In vitro/in vivo correlation: 
In vitro in vivo correlation (IVIVC) has been defined by US 
pharmacopoeia (USP) as the establishment of a relationship between a 
biological property, or a parameter derived from a biological property 
produced by a dosage form and a physicochemical characteristic of the 
same dosage form. FDA defined IVIVC as a predictable mathematical 
model describing the relationship between an in vitro property (usually 
the extent or rate of release) and a relevant in vivo response (e.g. 
plasma concentration or amount of drug absorbed). In vitro in vivo 
(IVIVC) is guidance for product development. 
3.6.1 Categories of correlation: 
The IVIVC was categorized by FDA into 3 levels, level A, B, 
and C (2) 
Level A: 
Is a predictive mathematical model for relationship between the 
entire in vitro release time and entire in vivo response time e.g. for 
plasma drug concentration or amount of drug absorbed. 
Level B: 
A predictive mathematical model for relationship between 
summary parameters that characterize the in vitro and in vivo time 
coarse e.g. relate mean in vitro dissolution time to the mean in vivo 
dissolution time or the mean residence time in vivo. 
Level C: 
A predictive mathematical model for relationship between the 
amount dissolved  in vitro at a particular time e.g. (Q60) or the time 
required for dissolution  of a fixed amount (T50%) and the in vivo 
parameters Cmax, AUC0-t (2) 
Using level A, in vitro in vivo correlation was done for both Voltaren 
retard and MT33.  
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The in vitro dissolution curve was compared to the drug plasma 
release curve which was obtained from the simple superimposition of 
the two mentioned curves which indicate the correlation. A plot of the 
fraction absorbed in vivo versus the fraction released in vitro was made. 
This relation is often linear with slope greater than 0.95. The intercept 
may or may not be zero, depending on the lag time for in vivo release 
or the non-instantaneous absorption rate resulting of dissolved non-
absorbed drug. 
 Currently accepted criteria are 80-125% of the reference using 
90% confidence interval. 
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Table (3.5): Voltaren retard in vitro in vivo correlation data.  
 
Time 
hr. 
Plasma C. 
µg/ml. 
Amount dissolved 
mg/ml 
Ln Value of amount 
dissolved 
0.5 0.2047 0 -2.01216 
1 0.2167 0.1337 -1.38669 
2 0.233 0.2499 -1.06711 
3 0.2406 0.344 -0.8308 
4 0.2482 0.4357 -0.68856 
5 0.2481 0.5023 -0.46061 
6 0.2479 0.6309 -0.38802 
7 0.2607 0.6784 -0.318 
8 0.2735 0.7276 - 
10 0.3063 - - 
12 0.2907 - - 
24 0.3087 - - 
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Figure 3.3 In vitro in vivo correlation of Voltaren retard. 
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Table (3.6): MT33 in vitro in vivo correlation data  
 
Time 
Hr. 
Plasma C. 
µg/ml. 
Amount dissolved 
mg/ml 
Ln Value for amount 
dissolved 
0.5 0.2595 0 -2.67365 
1 0.2706 0.069 -1.90381 
2 0.2967 0.149 -1.35518 
3 0.3034 0.2579 -0.9835 
4 0.3101 0.374 -0.74866 
5 0.3001 0.473 -0.57803 
6 0.2901 0.561 -0.4684 
7 0.3055 0.626 -0.37251 
8 0.3209 0.689 - 
9 0.3176 - - 
10 0.3142 - - 
11 0.3238 - - 
12 0.3333 - - 
24 0.4112 - - 
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Figure (3.4): In vitro in vivo correlation of MT33 
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Table (3.7): Ln values of diclofenac sodium from Voltaren retard (in vitro 
dissolution and in vivo plasma concentration). 
 
Ln values of in vitro  Diclofenac  
concentrations 
Ln values of in vivo Dicloenac 
concentrations 
2.01216 1.58621 
1.38669 1.529241 
1.06711 1.456717 
0.8308 1.424619 
0.68856 1.39352 
0.46061 1.393923 
0.38802 1.39473 
0.318 1.344385 
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Figure (3.5): Correlation of Ln values of Diclofenac sodium released 
from Voltaren retard (in vitro dissolution and in vivo 
plasma concentration). 
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Table (3.8): Ln values of Diclofenac sodium concentration from MT33 
(in vitro dissolution and in vivo plasma concentration). 
 
Ln values of in vitro Diclofenac 
concentrations 
Ln values of in vivo Diclofenac 
concentrations 
0.2047 1.349 
0.2167 1.3071 
0.233 1.215 
0.2406 1.1927 
0.2482 1.1708 
0.2481 1.2036 
0.2479 1.2375 
0.2607 1.1858 
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Figure (3.6): Correlation of Ln values of Diclofenac sodium released 
from MT33 (in vitro dissolution and in vivo plasma 
concentration). 
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3.7 Accelerated stability study of matrix tablets: 
The USP/NF has required expiration dates for all monograph drugs 
since January 1976 (10). The label should bear the expiration date 
limiting the period during which the oral tablet retains its full label 
potency if stored as directed. A set of storage temperatures was provided 
by USP/NF to cover the various conditions of storage. From the freezing 
of -10 οC, refrigerator between 2 - 8 οC, cool place between 8-15 οC, 
control temperature between 15 -30 οC, room temperature, up to 40 οC 
with protection of light and moisture. 
 Accelerated stability based on chemical kinetics was demonstrated 
by Garret and carper since 1955 (58). The WHO stated that the 
temperature and relative humidity for the accelerated stability conditions 
in climatic zone 1V as 40 + 2Cο  /75% + 5 RH for six months (59). 
In 1971 the food and drug administration (FDA) published a set of 
guide lines, Manufacturing and controls for investigational new drug 
application (IND) and new drug application (NDA) which defined in 
greater details the stability information required for new drug application 
(10). The tablet physical parameters in IND phase 111 are surface 
appearance, friability, fragility, hardness, disintegration, color, weight 
variation, odor, and moisture and dissolution rate. Nowadays many 
guidelines were used for stability. They include ICH (International 
conference for Harmonization), CPMP (Committee for proprietary 
medicinal products) FDA (Food and drug Administration) and WHO 
(World Health Organization) (59-63). 
 The purposes of stability study are to ensure the efficacy, safety 
and quality of drug, and shelf life determination. In 1987 the FDA 
published the guidelines for submitting documentation for stability of 
human drugs and biologics (10). They include tests for appearance, 
friability, hardness, color, odor, moisture, strength, and dissolution. The 
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stability should include at least three batches in a marketing container 
used for study under the specified storage conditions. The factors 
affecting stability are storage time, storage conditions, type of dosage 
form and container and closure systems. 
  Stress conditions in accelerated stability studies (64) in 
multi-temperatures and Arrhenius equation were used for estimation of 
shelf life of drugs. The Arrhenius Approach has several drawbacks, 
which apply for drugs with determined rate of reaction and the linear 
regression is applied even though the data are not linear. Above critical 
temperature with change of degradation mechanism this approach is 
invalid (65) 
In the Sudan, which has, different climatic conditions from the 
Sahara to the sub-tropical conditions made the stability of 
pharmaceuticals to be of crucial importance especially for a new drug 
delivery system.  
 The objectives of this study were to evaluate the content in 
accelerated stability of new matrix formulations of Diclofenac sodium 
100mg which was proved to be controlled release matrix delivery system. 
We also assessed the microbiological burden in gum matrix tablets, 
comparing preserved tablets with non-preserved ones. 
In a previous study (66) three controlled release matrix tablets from 
EudragitL100 6% plus Hydroxy-propyl-methyl-cellulose HPMC 20% 
(MT20). Guar gum15 % plus Gum Arabic 15% (MT33). Xanthan gum 
15% plus Gum Arabic 5% (MT34) were proved to be as new oral drug 
delivery systems. The formulas, MT33, MT34 were preserved with both 
0.18 % methylparaben and 0.02% propylparaben to give MT33p and 
MT34p consecutively. 
The incorporation of gums especially acacia was reported to be 
susceptible to microbiological contamination (67). Being susceptible to 
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such deterioration it was necessary to preserve these (MT33, MT34) gum 
containing formulae. The compendia method (BP) stated a limited bio-
burden in oral tablets with absence of the pathogenic bacteria as E. coli, 
Salmonella typhi, and Staphylococcus aurous. 
 Since a high temperature was considered in stability study 40 οC. 
The reaction rate of molecules is proportional to the collisions per unit 
time. Since the numbers of collisions increase with time the exponential 
dependence was as in Arhenius equation: 
 Log K = LogA - ∆H/2.303RT 
 K=Specific rate of degradation 
 R= gas constant (1.987 cal deg-1 mol-1) 
 A=Frequency factor (constant) 
 T=Absolute temperature (t οC+ 273.16 οC) 
 H=activation energy of the chemical reaction. 
In the usual range of activation energy for tablets formulation 
decomposition is 10-20 mol-1 (10). 
 
3.7.1 Materials and methods: 
3.7.1.1 Chemicals and reagents: 
All solvents were HPLC grade, while the other chemicals were of 
analytical grade. The standard Diclofenac sodium was from Horst von 
Valtier Hamburg, Germany. All solvents and reagents were purchased by 
Wafrapharma Laboratories Sudan. The internal standard was 
propylparaben from G. Amphray Laboratories India. Nutrient agar, 
Saubourauds dextrose agar was from Oxoid® LTD, Basingstroke, 
Hampshire, England. 
The stability studies were conducted on the five matrix tablets 
(MT20, MT33, MT34, MT33p, MT34p) with reference to physical 
appearance and content after storage in stability chamber Rumed, Rubarth 
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Apparate GmbH Germany, at 45 οC and 75% relative humidity for 6 
month (WHO reg.).  
3.7.1.2 Instrumentation: 
The stability studies were conducted on the five matrix tablets 
(MT20, MT33, MT34, MT33p, and MT34p) prepared by direct 
compression method containing 100 mg Diclofenac sodium. They all 
proved to be potentially controlled release matrix delivery systems. 
The study was done in darkened chamber (68). The storage 
conditions were used for zone 1, 11,111, and 1V for accelerated stability 
study (40 οC and 75%RH) which was designed for solid oral dosage 
forms, solids for reconstitution, dry and lyophilized powders in glass 
vials. Samples were kept in blister packing –PVC 250 µm, Aluminum foil 
25 µm. Content analysis was performed using isocratic high performance 
liquid chromatographic method, using C18 column and mobile phase of 
phosphate buffer at pH 3.5 and acetonitrile in combinations of (65 and 
35V/V). 20µL were injected each time, and flow rate was one ml/minute. 
Microbiological tests for matrix tablets(MT20, MT33, MT34, MT33p, 
MT34p) during accelerated stability study, were performed using BP 
1999 method appendix XV1C (69). 
3.8 Microbiological study during stability: 
Microbiological tests were done for six consecutive months. 10 
tablets from the controlled release matrix tablets were ground by 
triturating in a mortar. 100 mg 0f the resulting powder was dissolved in 
sterile 9ml sodium peptone buffer solution at pH 7. One ml from this 
solution was taken and transferred to a sterile test tube containing 9ml of 
sterile purified water. 9 ml sterile purified water was taken as a negative 
control.  
 1 ml from each of these tubes was transferred to a sterile Petri-dish, 
then the sterile nutrient agar or sterile Saubourauds dextrose agar was 
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poured in the Petri-dishes. Each experiment was done in replicates to 
minimize error. The nutrient agar plates were incubated at 32 οC for 48 
hours to enumerate bacterial growth. Saubouraud dextrose agar was 
incubated at 25 οC for 72 hours to observe the fungal colonies (69)     
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Chapter IV 
4. Results and Discussion 
4.1 In vitro diffusion analysis: 
The release from the different matrices MT20, MT33, MT34 and 
V.R in acidic pH 1.2 was less than 10% complying with the enteric – 
coated articles - general drug release standard (1). All these matrices are 
pH sensitive since the percentage release pattern was affected by pH 
change. At pH 2.1 MT20 and MT33 gave zero-order release with 
correlation coefficient(r) of 0.9977 and 0.9910, respectively. 
At pH 4.2 the release profile of MT34 was parallel to V.R. The 
release was steady at pH 5.5 for all matrices. At pH7.2 all the four 
matrices MT20, MT33, MT34 and V.R gave zero order release with 
correlations (r) MT20, r = 0.9966, MT 33, r =0.9899, MT34, r = 0.9992 
V.R, r = 0.9925 almost approaching unity (fig 4.7) 
The drug release data were fitted to the following equation (70) 
Mt/M∝  = Ktn     
Where   Mt/M∝ is the fraction of the released drug at time t, K is a 
constant related to structure and geometric characteristics of the release 
device (50). The diffusion exponents were 0.96, 1.15, 1.02 and 1.12 for 
MT20, MT33, and MT34, and V.R consecutively, showed case II type of 
release (zero order). 
4.2 In vitro result and discussion 
 Figures 4.1, 4.2, 4.3, 4.4, 4.5, 4.6 and 4.7 showed in vitro release 
profiles for different matrices MT20, MT33, MT34 and V.R in different 
pH gradients. 
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Figure (4.1): Percentage release of Diclofenac sodium at pH 1.2 
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Figure (4.2): Percentage release of Diclofenac sodium at pH 2.1 
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Figure (4.3): Percentage release of Diclofenac sodium at pH 4.2 
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Figure (4.4): Percentage release of Diclofenac sodium at pH 5.5 
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Figure (4.5): Percentage release of Diclofenac sodium at pH 6.5 
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Figure (4.6): Percentage release of Diclofenac sodium at pH 6.7 
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Figure (4.7): Percentage release of Diclofenac sodium at pH 7.2 
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Figure (4.8): Percentage release of Diclofenac Sodium from acidic pH 1.2 
and pH 7.2 buffer media 
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Table (4.1): Correlation coefficients comparison for different matrices 
and Voltaren retard 
 
Model Standards Std. error Pearson Correlation Sig.** 
1 VR 1.539 - 0.934 
2 MT20 0.475 0.993 0.865 
3 MT33 0.194 0.998 0.014 
4 MT34 0.495 0.994 0.698 
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The change of pH changed the pattern of release according to 
figures 4.1 to 4.7. Within the matrix tablet the environment is almost 
neutral (Dibasic calcium hydrogen phosphate dihydrate) when the solvent 
entered the matrix the environment of the matrix was changed and the 
rate of release was changed which agreed with Al-Tanni, and Tashtoush 
(71) findings. 
 The above matrix tablets (MT20, MT33, MT34) showed drug 
release of about 60% after eight hours time in pH 1.2 and pH 7.2 
consecutively (fig.4.8). HPMC as a non – pH dependent matrix (52) with 
combination of Eudragit L100 (anionic polymer based on methacrylic 
acid and methacrylate, with 50% free carboxylic acid group) in a ratio of 
20% HPMC to 6% Eudragit L100 changed the matrix to a pH sensitive 
one, with release profile changed with pH change. 
It has been reported that HPMC (72) and Eudragit L100 (71) 
separately gave controlled release matrix tablets and in   combination of 
HPMC and Eudragit L100-55 also gave controlled release of Diclofenac 
(71). Eudragit L100 is similar to EudragitL100-55 but with less viscosity 
(73), despite of that it gave a controlled release matrix eroded at pH 5.5 
and pH 7.2. Gum Arabic as a polysaccharide with heteropolysaccharide 
(Xanthan gum) formed a controlled matrix similar to guar gum plus gum 
Arabic but highly pH sensitive. Guar gum a galactomannan with Xanthan 
gum (heteropolysacharide) made cross-linking to form a controlled 
matrix agreed with Bhagwat et al. patency (USA patents 6,537,578), (49) 
but acacia alone has no controlled release action (74). 
4.3 Analytical result and discussion  
Sharp chromatograms were obtained each time for both C8 and 
C18 columns. The sample concentrations and the retention times using 
C8 column were shown in table 4.2. The retention time was found to be at 
about 14 minutes for C8. It was reported to be at 25 minutes for 
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Diclofenac sodium and 12 minutes for Diclofenac impurity at the 
detection wavelength 254 nm but at different analytical conditions (57).  
When Diclofenac sodium was injected alone the Rt was 7.9 
minutes. Ibuprofen when injected with Diclofenac sodium as internal 
standard, using C8 column the same retention time of about 13.3 minutes 
was obtained. The total peak areas (mAU*min) of both Diclofenac 
sodium and Ibuprofen (490.09) was almost equal to the summation of 
each separate peak area of Diclofenac sodium (438.11) and 
Ibuprofen(28.37), which was 466.478 with slight delay in retention time 
13.7 minutes. This pathochromic shifts may be due to the interaction of 
the pair of electrons in Diclofenac sodium with Ibuprofen. Giving the 
same overlapped peaks, Ibuprofen was replaced by propyl-paraben as 
internal standard. 
Analyzing the three matrix tablets using C18 column instead of C8, 
the retention time of Diclofenac sodium and peak area obtained were 
shown in table 4.3.  
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Table (4.2): Column C8 analysis: Content and Rt time: 
Matrix C.% Rt in minutes mAU*min 
MT20 
104 
101 
098 
099 
100 
14.3 
13.6 
13.7 
13.0 
14.0 
428.129 
424.415 
405.609 
435.174 
428.532 
MT33 
 
 
103 
100 
099 
096 
103 
13.9 
13.7 
13.7 
12.9 
13.9 
442.532 
418.828 
408.844 
421.488 
442.532 
MT34 
 
 
100 
101 
097 
100 
100 
13.9 
13.7 
14.0 
13.2 
13.9 
470.526 
425.847 
383.963 
436.544 
470.527 
Standard 
Diclofenac 
100 13.8 427.686 
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The retention time for Diclofenac from different matrices using C 
18 was found to be about 8 minutes which was less than C8 (14 minutes). 
 Ibuprofen retention time was 7.9 minutes, and the peak areas of 
the sample and Ibuprofen was 402 mAU almost approaching 410 mAU of 
both analyte and internal standard. 
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Table (4.3): Column C18 analysis: Content and retention time (Rt) 
Matrix C% Rt in minutes mAU*min 
MT20 
106 
108 
107 
105 
106 
7.5 
7.9 
7.9 
7.9 
7.9 
416.836 
426.651 
424.015 
415.834 
420.051 
MT33 
 
 
104 
104 
107 
108 
106 
7.5 
9.0 
8.0 
8.0 
8.0 
410.970 
411.854 
422.784 
425.022 
417.083 
MT34 
 
 
096 
096 
096 
094 
099 
8.9 
8.8 
8.0 
7.8 
7.8 
466.779 
468.300 
467.634 
458.841 
483.879 
Standard 
Diclofenac 100 8.0 486.737 
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Table (4.4): Statistics of content of tablets matrices (MT20, MT33, and 
MT34) using C8 and C18 columns 
  
percentage 
content N Mean 
Std. 
Deviation 
Std. Error 
Mean p-value 
C8 15 100.0000 2.07 .53 0.062 
C18 15 102.8000 5.06 1.31  
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The C8 column (25cm) was longer than C18, (10 cm), while both 
columns were lined with the micro sphere –100. The long side butyl 
chain of Ibuprofen may delay the separation process making the 
Ibuprofen to be separated at a lower rate than the Diclofenac sodium big 
molecule. The time for analysis with C18 (8 minutes) was nearly half the 
time withC8 (13.7 minutes).  
4.4 Bio-equivalence result and discussion 
In bio-equivalence study of the previous matrices evaluated Cmax, 
Tmax, t1/2, rate of absorption, mean residence time and elimination rate 
constant of the investigated drug compared with control drug. The mean 
plasma concentration of both control (Voltaren retard) (VR) and MT33 
were shown on table 4.5. The mean plasma profile was presented in fig 
4.9. 
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Table (4.5): Mean and standard deviation of plasma concentration of both 
control (Voltaren retard,VR) and MT33 
 
Time 
(Hours) 
Voltaren retard MT33 
0.5 0.2047 0.2595 
1 0.2167 0.2706 
2 0.233 0.2967 
4 0.2482 0.3101 
6 0.2479 0.2901 
8 0.2735 0.3209 
10 0.3063 0.3142 
12 0.2907 0.3333 
24 0.3087 0.4112 
Mean 0.2589 0.3118 
SD 0.0380 0.0441 
Minim. 0.2047 0.2595 
Maxim. 0.363 0.4112 
CV% 14.6775 14.1437 
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Figure (4.9): Mean (+ SD) plasma concentration versus time profiles 
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Analysis of variance (ANOVA) was shown for plasma 
concentrations (F-value) for both control and MT33 
(Table 4.6). No differences between control and MT33 at all levels of 
time up to 24 hours which advocate the bio – equivalence of the two 
products (53).   
 
 
 
Table (4.6): Analysis of variance for bio-equivalence parameters  
 
Parameter Formulation 
 
N Mean + SD p-value 
AUC0-24 VR 
MT33  
 
12 
12 
7.059+0.36 
7.776+0.36 
0.401 
AUC0-∞ VR 
MT33  
 
12 
12 
32.693+1.18 
35.052+1.18 
0.799 
Cmax VR 
MT33 
12 
12 
0.391+0.02 
0.425+0.02 
0.443 
Tmax 
 
VR 
MT33  
12 
12 
12.333+0.13 
12.583+0.13 
0.936 
Kel   
VR 
MT33  
12 
12 
0.021+0.001 
0.022+0.001 
0.894 
AUC0-
24/AUC0-inf. 
VR 
MT33  
12 
12 
0.300+0.002 
0.304+0.002 
0.959 
T1/2 VR 
MT33  
12 
12 
41.375+0.79 
39.795+0.79 
0.936 
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The other data of all the bio - equivalent studies were shown in the 
following (tables 4.7 -4.29). 
 
 
 
Table (4.7): Demographic Data and Sequence of administration of MT33 
and Voltaren retard (100mg) to twelve healthy male 
volunteers  
 
Subject 
No 
Subject 
ID 
Age 
Yrs 
Height 
Cm 
Weight 
Kg 
Period 1 Period 2 
1 MAH 26 
 
180 76 A B 
2 KHN 25 
 
164 60 A B 
3 MOH 28 
 
162 50 A B 
4 ABA 31 
 
173 53 A B 
5 ABH 35 
 
163 70 A B 
6 MOA 25 
 
167 58 A B 
7 MOR 24 
 
169 55 B A 
8 MMO 25 
 
172 58 B A 
9 SAM 41 
 
171 76 B A 
10 YOA 44 
 
179 86 B A 
11 MOM 25 
 
173 65 B A 
12 ALA 23 
 
170 55 B A 
Mean - 29.33 
 
170.25 63.50 - - 
+SD - 7.02 
 
5.74 11.17 - - 
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Table (4.8): Plasma concentrations (µg/ml) of Voltaren retard (100mg) 
after oral administration to twelve healthy male volunteers 
No Subject time 0.5 1 2 4 6 8 10 12 24 
1 MAH 0 0.299 0.326 0.323 0.373 0.400 0.371 0.385 0.458 0.253 
2 KHN 0 0.281 0.282 0.355 0.357 0.385 0.438 0.493 0.625 0.215 
3 MOH 0 0.316 0.326 0.133 0.115 0.345 0.352 0.400 0.510 0.224 
4 ABA 0 0.207 0.217 0.230 0.258 0.286 0.415 0.302 0.319 0.126 
5 ABH 0 0.378 0.341 0.359 0.416 0.250 0.310 0.311 0.401 0.382 
6 MOA 0 0.172 0.208 0.168 0.173 0.199 0.227 0.231 0.197 0.143 
7 MOR 0 0.169 0.224 0.222 0.225 0.377 0.374 0.198 0.162 0.165 
8 MMO 0 0.227 0.220 0.155 0.188 0.221 0.381 0.453 0.427 0.241 
9 SAM 0 0.191 0.214 0.227 0.253 0.326 0.236 0.246 0.187 0.222 
10 YOA 0 0.133 0.230 0.255 0.269 0.262 0.383 0.262 0.241 0.227 
11 MOM 0 0.136 0.135 0.389 0.230 0.128 0.102 0.097 0.088 0.1534 
12 ALA 0 0.093 0.074 0.162 0.117 0.104 0.088 0.112 0.091 0.107 
Mean  0 0.204 0.217 0.233 0.248 0.249 0.273 0.306 0.291 0.309 
SD  0 0.074 0.086 0.078 0.089 0.096 0.098 0.118 0.125 0.174 
C.V.,%  0 36.11 39.50 33.68 35.77 38.75 35.91 38.39 43.10 56.47 
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Table: (4.9): Plasma concentrations (µg/ml) of MT33 after oral 
administration to twelve healthy male volunteers 
 
 
Sub. 
No 
Sub. 
ID 
Zero 
time 
0.5 
hr 
1 
hr 
2 
hrs 
4 
hrs 
6 
hrs 
8 
hrs 
10 
hrs 
12 
hrs 
24 
hrs 
1 MAH 0 0.373 0.3176 0.32 0.3127 0.2435 0.391 0.3128 0.4204 0.3972 
2 KHN 0 0.2984 0.369 0.3147 0.363 0.3477 0.3986 0.3061 0.3167 0.3428 
3 MOH 0 0.4332 0.4704 0.4516 0.4432 0.393 0.3838 0.2996 0.2958 0.4114 
4 ABA 0 0.4221 0.4292 0.5154 0.4519 0.463 0.4959 0.4849 0.4987 0.4883 
5 ABH 0 0.266 0.2998 0.2973 0.4059 0.3289 0.3793 0.416 0.3648 0.3693 
6 MOA 0 0.1492 0.1936 0.1652 0.1828 0.1632 0.2124 0.2631 0.3748 0.5274 
7 MOR 0 0.209 0.2097 0.2391 0.2926 0.2333 0.2435 0.3507 0.2352 0.292 
8 MMO 0 0.2412 0.2604 0.2693 0.2657 0.2964 0.2545 0.2734 0.2666 0.2864 
9 SAM 0 0.3276 0.3127 0.3462 0.3408 0.3532 0.3113 0.3409 0.3511 0.5356 
10 YOA 0 0.0939 0.1003 0.3394 0.359 0.3709 0.4366 0.3641 0.3462 0.3418 
11 MOM 0 0.1325 0.1273 0.1202 0.1014 0.1138 0.1507 0.1442 0.1389 0.3424 
12 ALA 0 0.1678 0.1569 0.1823 0.2023 0.1737 0.1928 0.2147 0.39 0.2054 
Mean - - 0.2594 0.2705 0.29 0.3101 0.2900 0.3208 0.3142 0.3332 0.3783 
+SD - - 0.1138 0.1174 0.1138 0.1074 0.1053 0.1087 0.0891 0.0929 0.1001 
C.V.,% - - 0.0939 0.1003 0.1202 0.1014 0.1138 0.1507 0.1442 0.1389 0.2054 
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Table (4.10):  ANOVA of mean (+ SD) plasma concentration (µg /ml) of 
Voltaren retard (100 mg) and MT33 at each sampling time 
after oral administration: 
 
Time 
Hr/s 
Voltaren retard 
100mg MT33 
ANNOVA* 
NS** 
Zero 0 0  
0.5 0.20+0.07 0.26+0.11 0.176 
1 0.22+0.09 0.27+0.12 0.212 
2 0.23+0.08 0.30+0.11 0.125 
4 0.25+0.09 0.31+0.11 0.138 
6 0.25+0.10 0.29+0.11 0.316 
8 0.27+0.10 0.32+0.11 0.275 
10 0.31+0.12 0.31+0.09 0.855 
12 0.29+0.13 0.33+0.09 0.355 
24 0.31+0.17 0.41+0.10 0.243 
Minimum 0.20 0.26 - 
Maximum 0.30 0.41 - 
CV% 0.38 0.38 - 
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Table (4.11): Pharmacokinetic parameters of Diclofenac sodium after oral 
administration of Voltaren retard (1oo mg) to twelve 
healthy male volunteers 
 
 
No ID AUC0-t µg.hr/ml 
AUC0-∞ 
 
Cmax 
µg/ml Tmax Kel T1/2 
1 MAH 9.15 40.74 0.458 24 0.0145 47.79 
2 KHN 10.96 42.51 0.6247 24 0.0198 35 
3 MOH 8.53 33.49 0.5092 24 0.0204 33.97 
4 ABA 6.9 76.28 0.4149 10 0.0046 15.065 
5 ABH 8.14 27.13 0.4162 6 0.0211 32.84 
6 MOA 4.8 19.57 0.2306 12 0.0133 52.11 
7 MOR 5.26 14.91 0.3766 8 0.0168 41.25 
8 MMO 8.18 61.51 0.4529 12 0.008 86.63 
9 SAM 5.45 13.67 0.3256 8 0.0228 30.39 
10 YOA 6.74 40.66 0.3825 10 0.0021 33 
11 MOM 7.99 18.32 0.389 4 0.0085 81.53 
12 ALA 2.61 3.52 0.117 6 0.1 6.93 
Mean  7.06 30.42 0.3914 11.5 0.02099 41.38 
+ SD  2.254 21.094 0.129 7.426 0.0258 23.461 
Minimum  2.61 3.52 0.117 4 0.0021 6.93 
Maximum  10.96 76.28 0.6247 24 0.1 86.63 
C.V., %  31.93 69.34 32.96 64.57 122.92 56.7 
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Table (4.12): Pharmacokinetic parameters of Diclofenac sodium after oral 
administration of MT33 to twelve healthy male volunteers 
 
No ID AUC0-t (µg.hr/ml) 
AUC0-∞ 
 
Cmax 
µg/ml 
Tmax 
hrs Kel T1/2 
1 MAH 8.66 93.17 0.4204 12 0.0047 14.74 
2 KHN 7.93 59.87 0.3986 8 0.0066 16.5 
3 MOH 8.72 23.68 0.4704 1 0.0275 25.2 
4 ABA 11.41 28.269 0.4987 12 0.0018 38.5 
5 ABH 8.57 37.787 0.416 10 0.01 69.3 
6 MOA 7.99 26.5 0.5274 24 0.0285 24.32 
7 MOR 6.21 22.43 0.367 10 0.018 38.5 
8 MMO 6.42 54.15 0.2964 6 0.006 115.5 
9 SAM 8.95 24.17 0.5356 24 0.0352 19.69 
10 YOA 8.14 31.887 0.4366 8 0.0011 63.09 
11 MOM 4.35 8.9 0.3424 24 0.0752 39.22 
12 ALA 5.96 9.81 0.39 12 0.0534 12.98 
Mean  7.78 35.05 0.4 12.58 0.0192 39.8 
+ SD  1.82 23.78 0.07 7.54 0.023 29.991 
Minimum  4.35 8.9 0.2964 1 0.001 12.98 
Maximum  11.41 37.787 0.5274 24 0.0752 115.5 
C.V., %  23.39 67.85 17.5 59.94 119.79 75.35 
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Table (4.13): Summary Statistics of the pharmacokinetic parameters of 
Diclofenac sodium after oral administration of Voltaren 
retard (100mg) to twelve healthy male volunteers 
 
Period 1 
 
Variable 
 N Mean + SD Minimum Maximum C.V.,% 
AUC0-t 
(µg.hr/ml) 6 8.08 1.905 4.8 109.6 23.589 
AUC0-∞ 
(µg.hr/ml) 6 39.95 18.021 19.57 76.28 45.104 
Cmax 6 0.44 0.118 0.23 0.62 26.792 
Tmax 6 16.67 7.54 6 24 45.255 
Kel 6 0.016 0.0057 0.0046 0.021 36.825 
T1/2 6 36.13 11.91 15.06 52.11 32.979 
 
Period 2 
 
Variable N Mean + SD Minimum Maximum C.V.,% 
AUC0-t 
(µg.hr/ml) 6 6.038 2.078 2.610 8.180 34.416 
AUC0-∞ 
(µg.hr/ml) 6 25.432 21.509 3.520 61.510 84.577 
Cmax 6 0.341 0.116 0.117 0.453 34.296 
Tmax 6 8 2.828 4 12 36.053 
Kel 6 0.026 0.036 0.002 0.1 130.572
T1/2 6 46.622 31.217 6.93 86.63 66.958 
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Table (4.14): Summary Statistics of the pharmacokinetic parameters of 
Diclofenac sodium after oral administration of MT33 to 
twelve healthy male volunteers 
Period 1 
Variable N Mean + SD Minimum Maximum C.V.,% 
AUC0-t 
(µg.hr/ml) 6 8.88 1.285 7.93 11.41 14.479 
AUC0-∞ 
(µg.hr/ml) 6 44.879 27.090 23.68 93.17 60.368 
Cmax 6 0.455 0.050 0.3996 0.527 11.325 
Tmax 6 11.167 7.494 1 24 67.114 
Kel 6 0.013 0.01178 0.0018 0.0285 89.403 
T1/2 6 31.426 20.371 14.74 69.30 64.822 
 
Period 2 
Variable N Mean + SD Minimum Maximum C.V.,% 
AUC0-t 
(µg.hr/ml) 6 6.672 1.644 4.35 8.95 24.64 
AUC0-∞ 
(µg.hr/ml) 6 25.225 16.697 8.90 54.15 66.1969
Cmax 6 0.3946 0.0834 0.2964 0.5356 21.137 
Tmax 6 14 8 6 24 57.143 
Kel 6 0.0315 0.0288 0.0011 0.0752 49.695 
T1/2 6 48.1633 37.3604 12.980 115.50 77.570 
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Table (4.15): T-test for equality of means using Ln values. 
 
Variable N Formulation Mean + SD Sig. P- value (2 tailed) 
AUC0-24 
(µg.hr/ml) 12 
Control 
MT33 
1.896 
2.024 
0.38 
0.25 0.343 
AUC0-∞ 
(µg.hr/ml) 12 
Control 
MT33 
3.240 
3.355 
0.83 
0.68 0.714 
Cmax 12 
Control 
MT33 
1.008 
0.870 
0.43 
0.18 0.318 
Tmax 12 
Control 
MT33 
2.353 
2.295 
0.59 
0.86 0.849 
Kel 
 12 
Control 
MT33 
4.295 
4.439 
0.95 
1.33 0.763 
T1/2 12 
Control 
MT33 
3.545 
3.463 
0.69 
0.68 0.773 
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Table (4.16): Independent sample test for MRT and clearance: 
 
 
Parameter N Formulation Mean + SD Sig. P  (2 tailed)
MRT 12 Control MT33 
3.366 
4.034 
1.9 
2.2 0.428 
Clearance 12 Control MT33 
5.823 
4.328 
2.4 
3.2 0.526 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96
 
 
 
 
 
Table (4.17): Area Under the plasma concentration-time curve (AUC0-24) 
(µg.hr/ml) of Diclofenac sodium after oral administration of 
Voltaren retard and MT33 to twelve healthy male 
volunteers 
 
NO 
 ID 
Voltaren 
Retard (A) 
MT33 
(B) 
 
Voltaren 
Retard (A) 
*Ln data 
MT33 (B) 
*Ln data 
1 MAH 9.15 8.66 2.2138 2.1587 
2 KHN 10.96 7.93 2.3943 2.0706 
3 MOH 8.53 8.72 2.1656 2.1656 
4 ABA 6.9 11.41 1.9315 2.4345 
5 ABH 8.14 8.57 2.0968 2.1482 
6 MOA 4.8 7.99 1.5686 2.0782 
7 MOR 5.26 6.21 1.6601 1.8262 
8 MMO 8.18 6.42 2.1017 1.8594 
9 SAM 5.45 8.95 1.6956 2.1917 
10 YOA 6.74 8.14 1.9081 2.0968 
11 MOM 7.99 4.35 2.0782 1.4702 
12 ALA 2.61 5.96 0.9594 1.7851 
Mean  7.06 7.78 1.9 2.0234 
+ SD  2.25 1.82 0.3674 0.2399 
Minimum  2.61 4.35 0.9594 1.472 
Maximum  10.96 11.41 2.3943 2.1917 
C.V., %  31.93 23.39 19.315 11.856 
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Table (4.18): Area under the plasma concentration – to infinity time curve 
(AUC0-∞) (µg.hr/ml) of Diclofenac sodium after oral 
administration of the control and drug brand to twelve 
healthy male volunteers 
 
NO ID Voltaren Retard (A) MT33 (B) 
Voltaren 
Retard (A) 
*Ln data 
MT33 (B) 
*Ln data 
1 MAH 40.74 93.17 3.7072 4.5344 
2 KHN 42.51 59.87 3.75 4.922 
3 MOH 33.49 23.68 3.5112 3.1646 
4 ABA 76.28 28.269 4.3344 3.3418 
5 ABH 27.13 37.787 3.3006 3.632 
6 MOA 19.57 26.5 2.974 3.2921 
7 MOR 14.91 22.43 2.702 3.1104 
8 MMO 61.51 54.15 4.1191 3.9918 
9 SAM 13.67 24.17 2.6152 3.1851 
10 YOA 40.66 31.887 3.7052 3.4622 
11 MOM 18.32 8.9 2.908 2.1861 
12 ALA 3.52 9.81 1.2585 2.2834 
Mean  32.69 35.05 3.2405 3.3563 
+ SD  21.094 23.78 0.792132 0.759865 
Minimum  3.52 8.9 1.2585 2.1861 
Maximum  76.28 37.787 4.3344 4.5344 
C.V., %  69.34 67.85 24.4406 22.6380 
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Table (4.19): Peak plasma concentration (Cmax) (µg/ml) of Diclofenac 
sodium after oral administration of Voltaren retard and 
MT33 to twelve healthy male volunteers 
 
NO ID Voltaren Retard (A) MT33 (B) 
Voltaren 
Retard (A) 
*Ln data 
MT33 (B) 
*Ln data 
 
1 MAH 0.458 0.4204 0.78 0.84 
2 KHN 0.6247 0.3986 0.47 0.92 
3 MOH 0.5092 0.4704 0.67 0.75 
4 ABA 0.4149 0.4987 0.88 0.7 
5 ABH 0.4162 0.416 0.88 0.88 
6 MOA 0.2306 0.5274 1.48 0.64 
7 MOR 0.3766 0.367 0.98 1.05 
8 MMO 0.4529 0.2964 0.79 1.22 
9 SAM 0.3256 0.5356 1.12 0.62 
10 YOA 0.3825 0.4366 0.96 0.83 
11 MOM 0.389 0.3424 0.94 1.07 
12 ALA 0.117 0.39 2.15 0.94 
Mean  0.3914 0.4 1.01 0.87 
+ SD  0.129 0.07 0.41665 0.174062 
Minimum  0.117 0.2964 0.470 0.62 
Maximum  0.6247 0.5274 2.150 1.22 
C.V., %  32.96 17.5 41.3170 19.9039 
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Table (4.20): Analysis of variance of Cmax 
 
Parameter Formulation Mean SD p-value 
Cmax VR 0.391 0.129 0.443* 
 MT33 0.425 0.073  
 
  
 
 
. 
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Table (4.21): Summary Statistics of the area under the plasma 
concentration-time curve (AUC0-24) for Voltaren retard and 
MT33 
 
Formulation N* Mean*** SD p-value** 
Voltaren retard 100 mg 12 7.059 2.254 0.401 
MT33 12 7.776 1.819  
Periods***     
Period 1 12 7.376 1.937 0.923 
Period 2 12 7.459 2.217  
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Table (4.22): Summary Statistics of the area under the plasma 
concentration – time curve (AUC0-∞) for Voltaren retard and 
MT33 
 
Formulation N* Mean*** SD p-value**
Voltaren retard 100 mg 12 32.693 21.094 0.799 
MT33 12 35.052 23.785  
Periods     
Period 1 12 32.589 19.053 0.782 
Period 2 12 35.155 25.438  
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Table (4.23): Summary statistics of peak plasma concentration (Cmax) for 
Voltaren retard and MT33 
 
Formulation N* Mean*** SD p-value** 
Voltaren retard 100 mg 12 0.391 0.129 0.443 
MT33 12 0.425 0.073  
Periods     
Period 1 12 0.418 0.107 0.639 
Period 2 12 0.398 0.105  
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Table (4.24): Summary statistics of time to peak plasma concentration 
(Tmax) for Voltaren retard and MT33 
 
Formulation N* Mean*** SD p-value** 
Voltaren retard 100 mg 12 12.333 7.426 0.936 
MT33 12 12.583 7.537  
Periods     
Period 1 12 15.333 7.878 0.052 
Period 2 12 9.583 5.648  
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Table (4.25): Summary statistics of the elimination rate constant (Kel) for 
Voltaren retard and MT33 
 
Formulation N* Mean*** SD p-value** 
Voltaren retard 100 mg 12 0.021 0.026 0.894 
MT33 12 0.022 0.023  
Periods     
Period 1 12 0.024 0.022 0.708 
Period 2 12 0.019 0.027  
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Table (4.26): Summary statistics of the elimination half-life (t1/2) for 
Voltaren retard and MT33 
 
Formulation N* Mean*** SD p-value** 
Voltaren retard 100 mg 12 41.375 23.461 0.887 
MT33 12 39.795 29.991  
Periods     
Period 1 12 42.146 27.411 0.779 
Period 2 12 39.024 26.355  
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Table (4.27): Time of peak plasma concentration (Tmax) (Hrs) of 
Diclofenac sodium after oral administration of both 
Voltaren retard and test drug: 
 
No ID Voltaren 100mg Ln V.R MT33 Ln MT33 
1 MAH 24 3.178 12 2.4849 
2 KHN 24 3.178 8 2.0794 
3 MOH 24 3.78 1 0 
4 ABA 10 2.3025 12 2.4849 
5 ABH 6 1.7918 10 2.3025 
6 MOA 12 2.4849 24 3.178 
7 MOR 8 2.0794 10 2.3025 
8 MMO 12 2.4845 6 1.7918 
9 SAM 8 2.0794 24 3.178 
10 
 YOA 10 2.3025 8 2.0794 
11 
 MOM 4 1.3862 24 2.3025 
12 
 ALA 6 1.7918 12 2.4849 
Mean 
 - 12.33 2.512 12.58 2.5321 
Minimum 
 - 4 1.3863 1 0 
Maximum 
 - 24 3.178 24 3.178 
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Table (4.28): Elimination rate constant (Kel) of Diclofenac sodium after 
administration of VR and MT33 to twelve healthy male 
Volunteers  
 
No 
 ID 
Voltaren 
retard 
100mg 
Ln V.R MT33 Ln  T33 
1 MAH 0.0145 4.23361 0.0047 5.36019 
2 KHN 0.0198 3.92207 0.0066 5.02069 
3 MOH 0.0204 3.89222 0.0275 3.59357 
4 ABA 0.0046 5.3817 0.0018 6.31997 
5 ABH 0.0211 3.85848 0.01 4.60517 
6 MOA 0.0133 4.31999 0.0285 3.55785 
7 MOR 0.0168 4.08638 0.018 4.01738 
8 MMO 0.008 4.82831 0.006 5.116 
9 SAM 0.0228 3.78099 0.0352 3.34671 
10 YOA 0.0021 6.16582 0.0011 6.81245 
11 MOM 0.0085 4.76769 0.0752 2.5876 
12 ALA 0.1 2.30259 0.0534 2.92994 
Mean - 0.02099 3.86371 0.0192 3.95284 
+ SD - 0.0258 3.65738 0.023 -3.77226 
Minimum 
 - 0.0021 6.16582 0.001 -6.90776 
Maximum - 0.1 2.30259 0.0752 -2.5876 
C.V % - 122.92 4.811534 119.79 4.78574 
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Table (4.29): Elimination half life ( t1/2) (hrs) of Diclofenac sodium after 
administration of VR and MT33 to twelve healthy male 
Volunteers  
 
No ID Voltaren Ln V.R MT33 Ln MT33 
1 MAH 47.79 3.8668 14.73 2.6899 
2 KHN 35 3.5553 16.5 2.8034 
3 MOH 33.97 3.5255 25.2 3.2268 
4 ABA 15.07 2.7127 38.5 3.6507 
5 ABH 32.84 3.4916 69.3 4.2384 
6 MOA 52.11 3.9534 24.32 3.1913 
7 MOR 41.25 3.7197 38.5 1.3807 
8 MMO 86.63 4.4616 115.5 4.7493 
9 SAM 30.39 3.4141 19.69 2.9801 
10 YOA 33 3.465 63.09 4.1446 
11 MOM 81.53 4.401 39.22 3.669 
12 ALA 6.93 1.9356 12.98 2.5634 
Mean - 41.38 3.7228 39.8 3.6839 
+ SD - 23.46 3.1553 29.99 3.4009 
Minimum - 6.93 1.9359 12.98 2.5634 
Maximum - 86.63 4.4616 115.5 4.7492 
C.V % - 56.7 1.3957 76.35 4.3353 
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The mean plasma concentration following oral administration of 
MT33 (guar gum + gum Arabic) matrix tablet of Diclofenac sodium was 
shown in figure 4.9. Tmax of Diclofenac was 24+7.5 hrs and the peak 
concentration Cmax was 0.5274 + 0.07 µg/ml which showed insignificant 
difference (p>0.05) compared to Voltaren retard tablets 0.624+ 0.129. 
Tmax was 24+7.42 hrs (p>0.05).  
4.5 Stability study results and discussion: 
Diclofenac sodium contents from the different matrix tablets 
MT20, MT33, MT34, MT33p, and MT34p were presented as in the 
following tables (4.30- 4.36) after six months accelerated stability study. 
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Table (4.30): Initial readings of physical analysis of matrix tablets 10-07-
2005 
 
Formulae 
 
Content 
(%) Rt (Min.) 
Peak area 
(mAU) appearance Disintegration 
 
MT20 104 14.317 428.129 
White flat tablet 
free from spots 
Comply BP 
2000 
 
MT33 103 13.918 442.532 
White flat tablet 
free from spots 
Comply BP 
2000 
 
MT34 110 13.885 470.526 
White flat tablet 
free from spots 
Comply BP 
2000 
 
MT33p 97 14.333 416.900 
White flat tablet 
free from spots 
Comply BP 
2000 
 
MT34p 103 14.200 441.354 
White flat tablet 
free from spots 
Comply BP 
2000 
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Table (4.31): First month content analysis of matrix tablets 10-08-2005 
 
Formulation Content (%) Rt (Min.) Peak area  (mAU) 
MT20 100.9 13.600 424.415 
MT33 99.6 13.668 418.828 
MT34 101.3 13.735 425.847 
MT33p 103.7 13.683 435.999 
MT34p 102.3 13.667 430.194 
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Table (4.32): Second month content analysis of matrix tablets 10-09-2005 
 
 
Formulation Content (%) Rt(Min.) Peak area  (mAU) 
MT20 97.9 13.683 405.609 
MT33 98.7 13.683 408.844 
MT34 96.7 14.217 400.683 
MT33p 92.7 14.117 383.963 
MT34p 92.2 13.800 381.961 
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Table (4.33): Third month content analysis of matrix tablets 10-10-2005 
 
Formulation Content (%) Rt (Min.) Peak area  (mAU) 
MT20 99.3 12.950 435.174 
MT33 96.2 12.900 421.488 
MT34 99.6 13.200 436.544 
MT33p 96.7 13.127 423.823 
MT34p 100.98 13.150 442.423 
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Table (4.34): Fourth month content analysis of matrix tablets 10-11-2005 
 
Formulation Content (%) Rt (Min.) Peak area  (mAU) 
MT20 99.0 13.000 433.725 
MT33 96.0 12.950 422.254 
MT34 100.0 12.900 422.254 
MT33p 97.0 14.400 423.494 
MT34p 102.0 14.433 449.623 
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Table (4.35): Fifth month content analysis of matrix tablets 10-12-2005 
 
Formulation Content (%) Rt (Min.) Peak area (mAU) 
MT20 98.7 12.62 447.999 
MT33 95.0 13.73 430.336 
MT34 95.5 13.52 446.628 
MT33p 98.4 13.58 443.714 
MT34p 96.0 13.53 436.057 
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Table (4.36): Sixth month content analysis of matrix tablets 10-01-2006 
 
Formulae 
 
Content 
(%) 
Rt 
(Min.) 
Peak 
area 
(mAU) 
appearance Disintegration 
MT20 96.2 14.017 423.437 White flat tablet free from spots Comply BP 2000 
MT33 95.0 13.800 417.233 White flat tablet free from spots Comply BP 2000 
MT34 94.0 13.600 412.588 White flat tablet free from spots Comply BP 2000 
 
MT33p 93.0 14.233 410.517 
White flat tablet free 
from spots Comply BP 2000 
MT34p 93.0 14.133 409.388 White flat tablet free from spots Comply BP 2000 
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Diclofenac sodium content from the different matrix tablets was 
presented in table 4.37. The average of analysis of three matrix similar 
formulations was 95-105 % (B.P limit). 
 
 
Table (4.37) Summary of content: Diclofenac sodium Content from 
sample matrices: 
 
No Zero time 
1st 
month 
2nd 
Month 
3rd 
Month 
4th 
Month 
5th 
Month 
6th 
Month 
MT20 104+2% 101+1% 98+2% 99+0% 99+0% 99+2% 96+2% 
MT33 103+1% 100+2% 99+3% 96+3% 96+3% 95+2% 95+1% 
MT34 105+3% 101+1% 97+1% 100+1% 100+1% 96+1% 94+0% 
MT33p 097+5% 104+2% 93+3% 97+2% 97+2% 98+1% 93+1% 
MT34p 103+1% 102+0% 92+4% 101+2% 102+3% 96+1% 93+1% 
STD 100% 100% 100% 100% 100% 100% 100% 
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Figure (4.10): Stability profile of different Diclofenac formulae 
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Figure 4.10 shows the stability profile of the five preserved and 
non preserved tablet formulations. It was found to be between 90-105%. 
The two preserved formulae were out of the B.P limit after two months, 
while the other three formulae MT20, MT33p and MT34 were within the 
limit for five months. The two selected candidate formulas MT20 and 
MT33 were within the limit for the entire study time course which 
advocated their stability and expected reliability for use. Although the BP 
limit was 95% as the lower limit for stability study the 90% in MT33p 
and MT34p of the labeled potency were recognized as the minimum 
acceptable level (65), putting all the studied matrix tablets as passing the 
content requirements in the specified temperature and relative humidity 
(40C, and 75%RH) which agreed with Harpinder et al (75). No change in 
physical appearance, or organoleptic properties -color, odor and taste- 
was observed. 
The stability of the Diclofenac sodium matrix tablets (MT20, 
MT33, MT34, MT33p, MT34p) was analyzed by the simple rule of 
thumb for out of trend stability study which stated that the out of trend 
(OOT) result is a stability result  
that does not follow the expected trend, either in comparison with 
other stability batches or with respect to previous results collected during 
a stability study (PhRMA CMC statistics and stability expert team) (76). 
The sample was considered out of trend if: 
Rule one: Three of the consecutive results were outside some limit (BP). 
Rule two: The result is outside +5%of the initial result. 
Rule three: The result is outside + 3% of the previous result. 
Rule four: The result is outside +5% of the mean of all the previous 
results. 
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Table (4.38): Stability result from the application of rule one for matrix 
tablets  
(+) complying (-) non-complying: 
Matrix Zero time 
1st 
Month 
2nd 
Month 
3rd 
Month 
4th 
Month 
5th 
Month 
6th 
Month 
MT20 + + + + + + + 
MT33 + + + + + + + 
MT34 + + + + + + - 
MT33p + + - + + + - 
MT34p + + - + + + - 
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Table (4.39): Stability result from the application of rule two for matrix 
tablets 
(+) within the limit (-) out of the limit: 
Matrix Zero time 
1st 
Month 
2nd 
Month 
3rd 
Month 
4th 
Month 
5th 
Month 
6th 
Month 
MT20 104 + - + + + - 
MT33 103 + + + + + + 
MT34 110 + - + + - - 
MT33p 097 + + + + + + 
MT34p 103 + - + + - - 
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Table (4.40): Stability result from the application of rule three for matrix 
tablets 
(+) within the limit (-) out of the limit: 
Matrix Zero time 
1st 
Month 
2nd 
Month 
3rd 
Month 
4th 
Month 
5th 
Month 
6th 
Month 
MT20 104 + + + + + + 
MT33 103 + + - + + + 
MT34 110 - - + + - + 
MT33p 097 - - - + + - 
MT34p 103 + - - + - - 
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Table (4.41): Stability result from the application of rule four for matrix 
tablets (+) within the limit (-) out of the limit: 
 
Matrix Zero time 
1st 
Month 
2nd 
Month 
3rd 
Month 
4th 
Month 
5th 
Month 
6th 
Month 
MT20 104 101 + + + + + 
MT33 103 100 + + + + + 
MT34 110 101 + + + - - 
MT33p 097 104 + + + + + 
MT34p 103 102 - + + + - 
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4.6 Conclusion. 
 This study showed that combinations of guar gum plus gum 
Arabic, gum Arabic plus Xanthan, and HPMC plus Eudragit L100, in 
specific proportions could be used in matrix controlled release tablets 
prepared by direct compression. 
From the in vitro release at pH1.2 for 2 hours and pH7.2 for 8 
hours consecutively and from the  physical properties the best controlled 
release formula was MT33 (guar gum 15% plus Gum Arabic 15%). 
MT20, MT33 and MT34 had significant correlation at the 0.01 level 
(2tailed) compared to Voltaren retard (table 16). MT33 compared with 
Voltaren retard showed significant regression coefficient (0.703) with sig. 
of (0.014) within the released time (table 4.1). 
 All the three matrices MT20, MT33, and MT34 were pH sensitive 
with zero-order release at pH 7.2.  
 Analyzing the above oral controlled delivery systems (MT20, 
MT33, MT34) using C8 method, precise and accurate results were 
obtained compared to C18 column. The precision which was less in C8 
than C18 was abstracted from the  standard deviations (SD) and relative 
standard deviations (RSD) table (4.2,4.3). 
In this 100mg Diclofenac tablet which weighed about 165mg, the 
upper and lower permissible limits for content analysis were +7.5 % 
according to international standards (10). This agrees with the results 
obtained using C8 and C18 columns. 
From table (4.4), the standard deviations were 2.07and 5.06, and 
relative standard deviations were 2.07and 4.92 respectively. Based on t-
test no significant difference was found between contents measurement 
using C8 and C18 columns at p′-value of 0.05. (Observed t-value was 
0.062 compared to the theoretical value of 2.15). The confidence of 
interval of the difference of the mean was - 0.58 to 0.16. 
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 The retention time using C8 was almost double (13.7 minutes) the 
retention time using C18 column (8.0 minutes). This showed that the 
method of using C18 was advantageous over the BP 2000 method, since 
it was time sparing and was as similar as C8 method with no significant 
difference of content measurement.  
Bio-equivalence of MT33 which is controlled release formula 
containing Diclofenac sodium with specified (15%) amount of guar gum 
and gum Arabic as matrix tablets was compared with Voltaren retard a 
well known Diclofenac  
sodium which has controlled release action. No significant difference 
between the two formulations was observed. The rate and extent of 
absorption was almost the same with higher minimum effective 
concentration of MT33 formula at all the course interval of test up to 24 
hours (Tables 4.6, 4.7, 4.8). The bio- equivalence was determined from 
ratios of test /control peak plasma concentration (Cmax) which equals 
107.6% and area under the curve (AUC0-24) which equals 110.16% 
complying with the standard 90-125%.  
The stability profiles of the controlled release matrices (MT20, 
MT33, MT34, MT33p, and MT34p) were found to be between 90-105%. 
The two preserved matrices (MT33p, and MT34p) showed one reading 
out of the BP limit at the second and another one at six month , while the 
other two formulae MT20, MT33 were within the BP limit (95-105%) for 
six months which advocated their stability and expected reliability for 
use. MT34 was out of limit at the six month. 
From the application of out of trend stability rules (tables 4.38 – 
4.41), it has been found that MT33 which contains guar gum 15% and 
gum Arabic15 % as controlled matrix was the best formula. The second 
one was MT20 which contains Eudragit L100 6% and HPMC 20 %. No 
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change in physical appearance, or organoleptic properties (colour, door 
and taste) was observed.  
No microbiological growth (bacteria or fungi) was observed during 
a six month accelerated stability study in both preserved and non 
preserved matrices. This excludes the effect of preservation in these 
controlled release matrix delivery systems. 
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Appendix I: Percentage release of Diclofenac sodium at pH 1.2. 
Time (h) MT33 MT20 MT34 V.R √t(mins) 
1 0.07 0.08 0.07 0.48 7.74 
2 0.08 0.06 0.15 0.53 10.95 
3 0.11 0.23 0.11 0.43 13.42 
4 0.16 0.25 0.03 0.40 15.49 
5 0.12 0.27 0.04 0.45 17.32 
6 0.37 0.33 0.38 0.65 18.97 
7 0.22 0.17 0.05 055 20.49 
8 0.35 0.43 0.09 053 21.91 
 
 
 
 
 
 
 
 137
 
 
 
 
 
 
 
 
Appendix ІI: Percentage release of Diclofenac sodium at pH 2.1  
Time (h) MT33 MT20 MT34 V.R √t (mins) 
1 0.32 0.27 4.7 0.27 7.74 
2 0.71 0.42 3.5 0.80 10.95 
3 1.14 0.59 3.4 0.92 13.42 
4 1.61 0.79 3.3 0.89 15.49 
5 1.89 0.98 3.1 0.83 17.32 
6 2.34 1.14 2.6 0.16 18.97 
7 2.58 1.31 3.4 0.99 20.49 
8 2.62 1.43 3.1 1.04 21.91 
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Appendix III: Percentage release of Diclofenac sodium at pH 4.2 
Time (h) MT33 MT20 MT34 V.R √t (mins) 
1 2.6 1.21 1.30 1.80 7.74 
2 1.93 1.72 2.70 2.70 10.95 
3 2.38 1.85 2.40 1.90 13.42 
4 2.46 2.05 1.90 1.40 15.49 
5 1.58 1.20 3.60 4.00 17.32 
6 1.25 1.08 1.50 2.00 18.97 
7 1.76 1.47 0.80 1.30 20.49 
8 0.99 1.50 2.60 3.00 21.91 
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Appendix IV: Percentage release of Diclofenac sodium at pH 5.5 
Time (h) MT33 MT20 MT34 V.R √t (mins) 
1 6.2 27.93 25.65 12.8 7.74 
2 11.91 50.64 49.96 14.41 10.94 
3 16.87 55.01 57.46 15.21 13.42 
4 21.74 57.31 63.19 16.27 15.49 
5 26.33 58.21 65.61 17.17 17.32 
6 31.67 59.41 67.70 18.28 18.97 
7 45.51 60.11 68.54 19.68 20.47 
8 44.34 60.66 69.59 20.54 21.91 
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Appendix V: Percentage release of Diclofenac sodium at pH 6.5 
Time (h) MT33 MT20 MT34 V.R √t (mins) 
1 45.25 43.69 101.34 23.39 7.74 
2 65.12 94.11 - 32.73 10.95 
3 74.07 97.77 - 40.08 13.42 
4 84.38 100.85 - 48.92 15.49 
5 87.48 - - 55.83 17.32 
6 90.78 - - 62.96 18.97 
7 100.03 - - 69.38 20.49 
8 96.00 - - 74.58 21.91 
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Appendix VI: Percentage release of Diclofenac sodium at pH 6.7 
Time (h) MT20 MT33 MT34 V.R √t (mins) 
1 18.54 66.54 28.31 11.51 7.74 
2 27.77 97.37 93.97 19.82 10.95 
3 32.99 102.24 95.08 24.72 13.42 
4 37.51 - 99.52 29.88 15.49 
5 41.55 - 97.49 32.89 17.32 
6 45.40 - 95.59 39.14 18.97 
7 46.20 - 97.9 43.28 20.49 
8 52.51 - 101.60 46.73 21.91 
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Appendix VII: Percentage release of Diclofenac sodium at pH 7 
Time (h) MT33 MT20 MT34 V.R √t (mins) 
1 6.17 13.90 7.61 12.04 7.74 
2 13.37 23.89 16.31 22.49 10.95 
3 23.21 32.82 26.21 30.96 13.42 
4 33.63 40.73 35.35 39.21 15.49 
5 42.58 48.02 43.84 45.21 17.32 
6 50.46 54.37 52.41 56.78 18.97 
7 56.33 60.09 61.19 61.06 20.49 
8 62.01 66.04 67.33 65.48 21.91 
 
 
